<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006998</article-id><article-id pub-id-type="pmc">PMC11860511</article-id><article-id pub-id-type="doi">10.3390/v17020243</article-id><article-id pub-id-type="publisher-id">viruses-17-00243</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Proinflammatory Biomarkers and Clinical Factors Associated with Long-Term Mortality in People with HIV</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3920-1670</contrib-id><name><surname>Lembas</surname><given-names>Agnieszka</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-viruses-17-00243" ref-type="aff">1</xref><xref rid="af2-viruses-17-00243" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8257-2739</contrib-id><name><surname>Za&#x00142;&#x00119;ski</surname><given-names>Andrzej</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-17-00243" ref-type="aff">1</xref><xref rid="af2-viruses-17-00243" ref-type="aff">2</xref><xref rid="c1-viruses-17-00243" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Miku&#x00142;a</surname><given-names>Tomasz</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-viruses-17-00243" ref-type="aff">1</xref><xref rid="af2-viruses-17-00243" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Koz&#x00142;owska</surname><given-names>Joanna</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af1-viruses-17-00243" ref-type="aff">1</xref><xref rid="af2-viruses-17-00243" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Wierci&#x00144;ska-Drapa&#x00142;o</surname><given-names>Alicja</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-viruses-17-00243" ref-type="aff">1</xref><xref rid="af2-viruses-17-00243" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Madeddu</surname><given-names>Giordano</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00243"><label>1</label>Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, 02-091 Warsaw, Poland; <email>a.lembas@hotmail.com</email> (A.L.); </aff><aff id="af2-viruses-17-00243"><label>2</label>Hospital for Infectious Diseases in Warsaw, 01-201 Warsaw, Poland</aff><author-notes><corresp id="c1-viruses-17-00243"><label>*</label>Correspondence: <email>andrzejzaleski84@wp.pl</email>; Tel.: +48-22-33-55-340</corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>243</elocation-id><history><date date-type="received"><day>06</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>07</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>09</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>People with HIV (PWH) receiving antiretroviral therapy (ART), despite a similar life expectancy, have a higher incidence of comorbidities than the general population. This study assessed the influence of proinflammatory biomarkers and clinical factors on mortality of PWH. We included PWH hospitalized from 2009 to 2014 who continued ART until 2023. The baseline lipid profile, CD4+ cell count, platelets, CRP, PCT, TNF-&#x003b1;, VCAM-1, and HCV and HBV coinfection were evaluated. Multivariable logistic regression was used to evaluate factors associated with mortality. Among 72 PWH, 19 were lost to a follow-up and 13 died before 2023. The mean follow-up was 12.07 years, while the mean time to death was 4.32 years. The main causes of death were cancer (<italic toggle="yes">n</italic> = 7) and drug-related death (<italic toggle="yes">n</italic> = 4). In the multivariate analysis, HCV coinfection, CRP &#x02265; 5 mg/L, PCT &#x02265; 0.05 ng/mL, and VCAM-1 &#x02265; 922 ng/mL were associated with higher odds of death. Although people who died had lower total cholesterol and triglyceride concentrations, these parameters were not associated with mortality. Determining HCV coinfections and CRP, PCT, and VCAM-1 levels may help identify PWH at increased risk of death for intensified monitoring. Care should also be taken of PWH with normal lipid parameters.</p></abstract><kwd-group><kwd>human immunodeficiency virus (HIV)</kwd><kwd>mortality</kwd><kwd>proinflammatory biomarkers</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00243"><title>1. Introduction</title><p>Untreated human immunodeficiency virus (HIV) infection causes the progressive and continuous impairment of the immune system, resulting in the development of opportunistic infections and neoplasms, which are the clinical manifestations of acquired immunodeficiency syndrome (AIDS). Since the identification of HIV in 1983, approximately 40.1 million people have died of AIDS [<xref rid="B1-viruses-17-00243" ref-type="bibr">1</xref>,<xref rid="B2-viruses-17-00243" ref-type="bibr">2</xref>,<xref rid="B3-viruses-17-00243" ref-type="bibr">3</xref>]. At the beginning of the global HIV pandemic, no antiretroviral therapy (ART) was available, which made AIDS-related diseases the main cause of death among people with HIV (PWH) [<xref rid="B4-viruses-17-00243" ref-type="bibr">4</xref>]. Current studies suggest that PWH receiving effective antiretroviral therapy have similar life expectancies as the general population, albeit with a higher incidence of comorbidities [<xref rid="B5-viruses-17-00243" ref-type="bibr">5</xref>].</p><p>The mechanisms by which the risk of comorbidities is increased in PWH are complex and multifactorial and include accelerated aging, lifestyle, ART toxicity, and other viral coinfections [<xref rid="B6-viruses-17-00243" ref-type="bibr">6</xref>,<xref rid="B7-viruses-17-00243" ref-type="bibr">7</xref>,<xref rid="B8-viruses-17-00243" ref-type="bibr">8</xref>]. The chronic stimulation of inflammation by HIV itself plays an important role in the increased inflammatory status. Several molecules promote inflammation in HIV infection, including the C-reactive protein (CRP), whose concentrations are higher in PWH in comparison to the general population, and interleukin-6, whose high circulating levels are associated with HIV replication [<xref rid="B9-viruses-17-00243" ref-type="bibr">9</xref>,<xref rid="B10-viruses-17-00243" ref-type="bibr">10</xref>]. HIV also contributes to the production of interleukin-1&#x003b2; via the transformation of pro-interleukin-1&#x003b2; into bioactive interleukin-1&#x003b2;, which is associated with the progression to AIDS [<xref rid="B11-viruses-17-00243" ref-type="bibr">11</xref>]. Replicating HIV induces a higher tumor necrosis factor alpha (TNF-&#x003b1;) serum concentration, and the overexpression of transforming growth factor beta (TGF-&#x003b2;) in PWH promotes viral replication and plays an important role in the progression of HIV infection [<xref rid="B12-viruses-17-00243" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-00243" ref-type="bibr">13</xref>]. Other proinflammatory factors in HIV are the adhesion molecules vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1), which mediate inflammation and promote leukocyte migration, whose expression is stimulated by the HIV-Tat-1 protein [<xref rid="B14-viruses-17-00243" ref-type="bibr">14</xref>]. Other mechanisms currently being examined include CD4+ lymphocyte depletion, cellular reservoirs of HIV, increased intestinal permeability and gut microbiome impairment, and altered cholesterol and glucose metabolism. Another important proinflammatory mechanism involves cell activation biomarkers, including CD38 and HLA-DR. CD38 is a glycoprotein that plays an important role in regulating the differentiation and activation state of the cell. During early HIV infection, expression of the CD38 molecule is significantly increased. Higher expression levels of CD38 on CD4+ T lymphocytes are associated with more rapid development of AIDS [<xref rid="B15-viruses-17-00243" ref-type="bibr">15</xref>]. The expression of HLA-DR on CD4+ T lymphocytes correlates with the level of total HIV DNA contributing to HIV persistence. HLA-DR+ cells are crucial in HIV infections because of their ability to release the virus when stimulated. The proportion of intact viral DNA sequences in the proliferative HLA-DR+ subset is high, which suggests they are critical in maintaining HIV infections [<xref rid="B16-viruses-17-00243" ref-type="bibr">16</xref>].</p><p>PWH are also more prone to develop comorbidities because of unhealthy behaviors such as smoking, alcohol intake, and stimulant or other drug usage [<xref rid="B17-viruses-17-00243" ref-type="bibr">17</xref>]. In people with HIV, people who inject drugs (PWID) may be especially vulnerable to concomitant diseases and have a higher risk of premature death for multiple reasons. For example, because of stigmatization, PWID may have limited access to HIV testing and antiretroviral therapy [<xref rid="B18-viruses-17-00243" ref-type="bibr">18</xref>]. Moreover, PWID often have unstable lives and may be less likely to adhere to ART, which may result in higher proinflammatory molecule concentrations and a higher risk of comorbidities and mortality [<xref rid="B19-viruses-17-00243" ref-type="bibr">19</xref>].</p><p>Effective ART leads to a decrease in the concentrations of the majority of proinflammatory molecules, although most remain higher than in the general population [<xref rid="B20-viruses-17-00243" ref-type="bibr">20</xref>,<xref rid="B21-viruses-17-00243" ref-type="bibr">21</xref>]. The prevalence of smoking, alcohol intake, and drug use in PWH remains higher than in the general population, increasing the risk of comorbidities, like neoplasms and cardiovascular disease (CVD), and premature death. This situation is particularly illustrated by the phenomenon that, in the general population, mortality rates from CVD are decreasing, whereas among PWH, they are increasing, mainly because of heart failure and stroke [<xref rid="B22-viruses-17-00243" ref-type="bibr">22</xref>,<xref rid="B23-viruses-17-00243" ref-type="bibr">23</xref>]. Despite more chronic conditions, PWH have a less pronounced increase in the risk of death than those with fewer conditions, compared with the general population [<xref rid="B24-viruses-17-00243" ref-type="bibr">24</xref>]. This might be explained by the fact that PWH have multiple medical appointments due to HIV infection and, therefore, undergo regular and general health assessments and early treatment of comorbidities.</p><p>This study assessed the influence of proinflammatory biomarkers and clinical factors on long-term all-cause mortality in PWH treated with ART. An additional aim of the study was to evaluate factors impacting the mortality of PWH who inject drugs and HIV/HCV-coinfected individuals.</p></sec><sec id="sec2-viruses-17-00243"><title>2. Materials and Methods</title><sec sec-type="subjects" id="sec2dot1-viruses-17-00243"><title>2.1. Patients</title><p>The study included the population of adult PWH hospitalized between 2009 and 2014. The inclusion criteria were HIV infection, regardless of the stage of the disease and time of treatment, continuing care in the HIV treatment center until 2023, and age 18 or older. The exclusion criteria were lipid-lowering therapy and signs of acute infection at the point of blood collection, including fever, cough, dyspnea, diarrhea, vomiting, dysuria, and skin infection. Patients receiving lipid-lowering agents were excluded in order to assess the differences in lipid parameters in between-group comparisons. Patients with infection were excluded to ensure that the elevation in proinflammatory biomarkers did not result from acute infection and may be assessed as a risk factor for long-term mortality.</p></sec><sec id="sec2dot2-viruses-17-00243"><title>2.2. Assessments</title><p>This was an observational, retrospective study. All patients underwent physical examination and laboratory testing. Each included patient was asked about the time of HIV infection diagnosis, the time of introduction of ART, concomitant disorders, and administered medications. Information about age, gender, education level, socio-economic status, and intravenous drug use was collected. Fasting blood samples were collected for total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride level, CD4+ cell count, platelets, C-reactive protein, procalcitonin (PCT), TNF-&#x003b1;, and VCAM-1. The VCAM-1 and TNF-&#x003b1; serum levels were evaluated by enzyme-linked immunosorbent assay (Human sVCAM-1/CD106 Quantikine ELISA and Human TNF-alpha Quantikine ELISA, R&#x00026;D Systems, respectively). All patients were assessed for hepatitis C virus (HCV) and hepatitis B virus (HBV) coinfection. HCV coinfection was confirmed by obtaining a positive HCV RNA, and HBV coinfection was confirmed by obtaining a positive HBs antigen or HBV DNA.</p></sec><sec id="sec2dot3-viruses-17-00243"><title>2.3. Long-Term Evaluation</title><p>All included patients were analyzed in 2023 in terms of death from any cause. Among patients who died, the time and cause of death were analyzed. The laboratory results and demographic data obtained in 2009&#x02013;2014 were evaluated as long-term risk factors for death. The applied schemes of ART were not included in the analysis because of multiple switches in regimens during the observation period.</p></sec><sec id="sec2dot4-viruses-17-00243"><title>2.4. Statistical Analysis</title><p>The Shapiro&#x02013;Wilk test was performed to verify the normality of the distributions in the analyzed variables. The two-sample Student <italic toggle="yes">t</italic>-test or Mann&#x02013;Whitney U test was used to evaluate the difference in the mean values among quantitative variables, and &#x003c7;<sup>2</sup> or Fisher exact tests were performed for categorical variables. ROC curves and the Youden index were used to choose an appropriate cutoff point for VCAM-1 and TNF-&#x003b1; concentrations. Univariate and multivariable logistic regression analysis was used to evaluate the factors associated with odds of death during the observation period. Multivariable logistic regression was adjusted by age (&#x0003c;35 years old vs. &#x02265;35 years old) and gender (male vs. female). The Kaplan&#x02013;Meier estimator was used to estimate patients&#x02019; survival. The <italic toggle="yes">p</italic>-value was set at 0.05. All statistical analyses were performed using Python 3.7 software and Statistica 13.1 program (StatSoft Poland, Krak&#x000f3;w, Poland).</p></sec><sec id="sec2dot5-viruses-17-00243"><title>2.5. Ethical Approval</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Medical University of Warsaw, Poland (AKBE/128/2021).</p></sec></sec><sec sec-type="results" id="sec3-viruses-17-00243"><title>3. Results</title><sec sec-type="subjects" id="sec3dot1-viruses-17-00243"><title>3.1. Patients</title><p>The study included 72 patients assessed in 2009&#x02013;2014. Among them, 40 (55.56%) patients were alive in 2023, 13 (18.06%) patients had died, and 19 (26.39%) patients were lost at a follow-up. The reasons for the loss of a follow-up included moving to another treatment center (<italic toggle="yes">n</italic> = 10) and discontinuing care (<italic toggle="yes">n</italic> = 9). The mean follow-up was 12.07 years (min 9.22 years, max 13.78 years). In the analyzed cohort, 39 (54.17%) of the population were PWID. All PWID in the study had primary or secondary education and did not have regular employment. At baseline, one person was receiving anticoagulants because of deep vein thrombosis, two patients were receiving hypotensive drugs, and one patient was receiving oral antihyperglycemic treatment. Significant differences in analyzed parameters in the people who died and those who lived are presented in <xref rid="viruses-17-00243-t001" ref-type="table">Table 1</xref>.</p><p>We observed significant differences in mean values of the duration of HIV infection, the presence of HCV coinfection, and serum concentrations of CRP, PCT, total cholesterol, triglycerides, and VCAM-1 among patients who lived and patients who died. All people diagnosed with HCV who stayed in care received HCV treatment with direct-acting antiviral agents with sustained virologic response at post-treatment week 24. Four patients died before the treatment was implemented.</p></sec><sec id="sec3dot2-viruses-17-00243"><title>3.2. Death</title><p>Among patients who died, the mean time to death was 4.32 years (min. 0.34, max. 11.12 years). The causes of death were cancer (<italic toggle="yes">n</italic> = 7), drug-related deaths (<italic toggle="yes">n</italic> = 4), COVID-19 (<italic toggle="yes">n</italic> = 1), and septic shock (<italic toggle="yes">n</italic> = 1). Among patients who died of cancer, the causes of death were Hodgkin&#x02019;s lymphoma (<italic toggle="yes">n</italic> = 2), esophageal cancer (<italic toggle="yes">n</italic> = 2), Kaposi sarcoma (<italic toggle="yes">n</italic> = 1), cervical cancer (<italic toggle="yes">n</italic> = 1), and bladder cancer (<italic toggle="yes">n</italic> = 1). There were no cancer diagnoses in patients who lived. In the group of people who died because of drug-related deaths, two individuals died of mental illness and two because of unintentional overdosing. The Kaplan&#x02013;Meier curve is presented in <xref rid="viruses-17-00243-f001" ref-type="fig">Figure 1</xref>.</p></sec><sec id="sec3dot3-viruses-17-00243"><title>3.3. Factors Associated with the Risk of Death</title><p>We next analyzed whether clinical and immunological biomarkers were associated with the risk of death among people with HIV. We assessed the cutoff point of 922 ng/mL for VCAM-1 and 43.45 pg/mL for TNF-&#x003b1; using the Youden index. The remaining parameters were assessed according to normal limits. The ROC curves for VCAM-1 and TNF-&#x003b1; are presented in <xref rid="viruses-17-00243-f002" ref-type="fig">Figure 2</xref>.</p><p>The analyzed clinical factors associated with the risk of death are shown in <xref rid="viruses-17-00243-t002" ref-type="table">Table 2</xref>.</p><p>The univariate analysis showed that age &#x02265;35 years old, HCV coinfection, CRP &#x02265; 5 mg/L, PCT &#x02265; 0.05 ng/mL, VCAM-1 &#x02265; 922 ng/mL, and HDL cholesterol &#x02264; 1 mmol/L were associated with higher odds of death. In the multivariable analysis, only HCV coinfection, CRP &#x02265; 5 mg/L, PCT &#x02265; 0.05 ng/mL, and VCAM-1 &#x02265; 922 ng/mL were significant risk factors for death.</p></sec><sec id="sec3dot4-viruses-17-00243"><title>3.4. Factors Associated with Mortality of PWID</title><p>The majority (54.17%) of the study population declared intravenous drug use. In this population, 11 patients died. The causes of death were cancer (<italic toggle="yes">n</italic> = 5), drug-related deaths (<italic toggle="yes">n</italic> = 4), COVID-19 (<italic toggle="yes">n</italic> = 1), and septic shock (<italic toggle="yes">n</italic> = 1). We analyzed factors associated with the risk of death among PWH who inject drugs. The results are presented in <xref rid="viruses-17-00243-t003" ref-type="table">Table 3</xref>.</p><p>Among PWH who inject drugs, only HCV coinfection and CRP &#x02265; 5 mg/L were significant risk factors for death.</p></sec><sec id="sec3dot5-viruses-17-00243"><title>3.5. Factors Associated with Cancer Incidence</title><p>Cancer was the primary cause of death in the study population. There were no cases of cancer in patients who lived. We evaluated factors associated with the risk of death due to cancer among PWH. The results are presented in <xref rid="viruses-17-00243-t004" ref-type="table">Table 4</xref>.</p><p>In our analysis, PCT &#x02265; 0.05 ng/mL and VCAM-1 &#x02265; 922 ng/mL were independent risk factors for cancer incidence among PWH.</p></sec><sec id="sec3dot6-viruses-17-00243"><title>3.6. Differences in Analyzed Parameters in PWH with HCV Coinfection</title><p>Since HCV coinfection was a significant risk factor for death in PWH and also in PWH who inject drugs, we evaluated the differences in mean analyzed parameters between HIV/HCV-coinfected individuals who died and those who lived. In the analyzed subpopulation, there were eight people who died and ten people who lived. The results are presented in <xref rid="viruses-17-00243-t005" ref-type="table">Table 5</xref>.</p><p>Individuals with HIV/HCV coinfection who died had significantly higher concentrations of VCAM-1 and significantly lower concentrations of HDL cholesterol.</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-17-00243"><title>4. Discussion</title><sec id="sec4dot1-viruses-17-00243"><title>4.1. Cause of Death Among PWH</title><p>The study was a long-term observation of all-cause mortality of PWH receiving ART. From the initial study population of 72 patients, we observed 74%. Among them, 25% died during the observation period. The main cause of death was cancer and drug-related deaths. According to current research, the most prevalent causes of death of PWH include AIDS, non-AIDS malignancy, and cardiovascular reasons. Although AIDS is still the main cause of death in untreated PWH, the rates of death due to AIDS are declining [<xref rid="B25-viruses-17-00243" ref-type="bibr">25</xref>]. In our cohort, there were no deaths due to AIDS; however, our study included only patients who were receiving ART and regularly attended follow-up. The majority of deaths were due to cancer, which corresponds with current research [<xref rid="B25-viruses-17-00243" ref-type="bibr">25</xref>]. In our analysis, cancer incidence in PWH was related to increased levels of PCT and VCAM-1. Our findings correspond with current research, and procalcitonin is being evaluated as a prognostic marker of cancer patients [<xref rid="B26-viruses-17-00243" ref-type="bibr">26</xref>]. Increased PCT concentrations may be an indication of non-small cell lung cancer and may be useful in the follow-up of medullary thyroid cancer [<xref rid="B27-viruses-17-00243" ref-type="bibr">27</xref>,<xref rid="B28-viruses-17-00243" ref-type="bibr">28</xref>]. VCAM-1 may be linked to the development of cancer [<xref rid="B29-viruses-17-00243" ref-type="bibr">29</xref>], and elevated concentrations of VCAM-1 have been found in the peripheral blood of patients with cancer [<xref rid="B30-viruses-17-00243" ref-type="bibr">30</xref>].</p><p>The second most prevalent cause of death in our population was drug-related death; 30% of deaths were related to intravenous drug use (mental illness in people who inject drugs (15%) and drug abuse (15%)). One study showed that PWH who inject drugs have higher mortality rates than PWH who do not inject drugs, and in this population, drug-related deaths accounted for 45.5% of all deaths [<xref rid="B31-viruses-17-00243" ref-type="bibr">31</xref>]. In our cohort, PWID accounted for over 50% of all analyzed patients. In this population, HCV coinfection and CRP &#x02265; 5 mg/L were independent risk factors for mortality. HCV coinfection is prevalent in PWID since it is estimated that 52.3% of all PWID are HCV-antibody positive [<xref rid="B32-viruses-17-00243" ref-type="bibr">32</xref>]. Its incidence enhances the mortality of PWID since HCV infection is a known risk factor for mortality and cancer, especially in HIV/HCV-coinfected individuals [<xref rid="B33-viruses-17-00243" ref-type="bibr">33</xref>]. CRP levels of PWID with no acute infection have not been extensively studied; however, it is possible that PWID experience increased levels of proinflammatory biomarkers resulting from the detectable HIV viral load that is prevalent in this population [<xref rid="B34-viruses-17-00243" ref-type="bibr">34</xref>].</p></sec><sec id="sec4dot2-viruses-17-00243"><title>4.2. Possible Mechanisms of Premature Death Among PWH</title><sec id="sec4dot2dot1-viruses-17-00243"><title>4.2.1. Proinflammatory Biomarkers</title><p>One possible explanation of mortality in PWH is proinflammatory mechanisms. It was observed that PWH have higher levels of proinflammatory biomarkers than the general population. Studies show elevated CRP, D-Dimer, interleukins 1&#x003b2;, 6, 11, and 27, TNF-&#x003b1;, TGF-&#x003b2;, cell adhesion molecules, and others in PWH compared to healthy controls [<xref rid="B35-viruses-17-00243" ref-type="bibr">35</xref>,<xref rid="B36-viruses-17-00243" ref-type="bibr">36</xref>,<xref rid="B37-viruses-17-00243" ref-type="bibr">37</xref>,<xref rid="B38-viruses-17-00243" ref-type="bibr">38</xref>]. Even when receiving ART and with a suppressed HIV viral load, the levels of these biomarkers are still elevated compared to healthy controls [<xref rid="B35-viruses-17-00243" ref-type="bibr">35</xref>,<xref rid="B36-viruses-17-00243" ref-type="bibr">36</xref>,<xref rid="B37-viruses-17-00243" ref-type="bibr">37</xref>].</p><p>A chronic increase in CRP levels, one of the most prevalent markers of inflammation, is also a well-known risk factor for CVD and a predictor of all-cause mortality [<xref rid="B38-viruses-17-00243" ref-type="bibr">38</xref>,<xref rid="B39-viruses-17-00243" ref-type="bibr">39</xref>]. There are reports suggesting that higher levels of CRP may be related not only to CVD and all-cause mortality but also to higher odds of death due to cancer, which is a very common cause of death in PWH [<xref rid="B40-viruses-17-00243" ref-type="bibr">40</xref>]. In PWH, increased levels of CRP are also associated with a higher HIV viral load, microbial translocation, immune activation, and mortality [<xref rid="B9-viruses-17-00243" ref-type="bibr">9</xref>]. Based on the former research, we evaluated whether the elevation of CRP concentration may also be a long-term mortality predictor in PWH. We found that CRP &#x02265; 5 mg/L in PWH with no signs of acute infection was associated with higher odds of death. Our findings correspond with research suggesting that higher baseline CRP in PWH is associated with higher all-cause mortality [<xref rid="B41-viruses-17-00243" ref-type="bibr">41</xref>]. Studies also indicate that even people with CD4+ cell count &#x0003e; 500 cells/&#x000b5;L experience intensified proinflammatory processes, resulting in an increase in CRP concentrations and mortality. People with HIV with CRP &#x0003e; 3 mg/L had 2.7-fold higher odds of death during the 5-year observation period than those with CRP &#x0003c; 1 mg/L [<xref rid="B42-viruses-17-00243" ref-type="bibr">42</xref>]. In our analyses, CRP correlated with higher odds of death in the entire PWH cohort, as well as in the subgroup of PWH who inject drugs. It was observed that PWID experience higher levels of CRP, which also might contribute to increased vulnerability to death [<xref rid="B43-viruses-17-00243" ref-type="bibr">43</xref>].</p><p>Procalcitonin, together with CRP, is a marker for systemic inflammation and an important diagnostic marker of sepsis that is used for the diagnosis and prediction of the severity of infection [<xref rid="B44-viruses-17-00243" ref-type="bibr">44</xref>]. PCT may also be produced because of noninfectious causes, such as surgery, shock, burn injury, trauma, chronic kidney disease, and liver cirrhosis [<xref rid="B44-viruses-17-00243" ref-type="bibr">44</xref>,<xref rid="B45-viruses-17-00243" ref-type="bibr">45</xref>]. There are reports that suggest that an increased PCT level is a predictive marker of mortality in trauma and also an independent risk factor associated with poor prognosis in cancer patients [<xref rid="B26-viruses-17-00243" ref-type="bibr">26</xref>,<xref rid="B46-viruses-17-00243" ref-type="bibr">46</xref>]. There are few studies evaluating the predictive value of PCT in HIV infection. The studies assessing the impact of PCT concentrations on long-term mortality in patients with no acute infection are also limited. In a study by Zhang et al., elevated PCT levels were identified as an independent risk factor for mortality of HIV/<italic toggle="yes">Talaromyces marneffei</italic> coinfection [<xref rid="B47-viruses-17-00243" ref-type="bibr">47</xref>]. Osawa et al. showed that increased PCT levels may predict mortality in tuberculosis patients with no HIV infection [<xref rid="B48-viruses-17-00243" ref-type="bibr">48</xref>]. Our research corresponds with these findings since we observed significantly higher odds of death among patients with PCT serum concentrations of &#x02265;0.5 ng/dL. To our knowledge, our study is the first to evaluate PCT concentrations as a long-term mortality risk in PWH with no acute infection.</p><p>VCAM-1 is a cell adhesion molecule [<xref rid="B49-viruses-17-00243" ref-type="bibr">49</xref>]. Chronic overexpression of VCAM-1, which was observed in PWH, promotes proatherogenic mechanisms and increases cardiovascular risk [<xref rid="B50-viruses-17-00243" ref-type="bibr">50</xref>]. We observed that VCAM-1 &#x02265; 922 ng/mL was associated with higher mortality rates. Our findings correspond with other research, which suggests that VCAM-1 may be a biomarker for predicting the risk of HIV-1 disease progression, morbidity, and mortality [<xref rid="B51-viruses-17-00243" ref-type="bibr">51</xref>]. In a study by Affi et al., VCAM-1 baseline concentrations &#x02265; 1458 ng/mL were associated with higher mortality rates of PWH during 30 months of observation [<xref rid="B52-viruses-17-00243" ref-type="bibr">52</xref>]. Interestingly, in PWH, VCAM-1 levels before ART implementation were significantly associated with mortality, independently of whether ART was started immediately or deferred [<xref rid="B35-viruses-17-00243" ref-type="bibr">35</xref>]. VCAM-1 is also currently being evaluated as a biomarker of mortality in other populations. For example, elevated VCAM-1 increases the risks of sepsis, septic shock, multiple-organ dysfunction syndrome, and death [<xref rid="B53-viruses-17-00243" ref-type="bibr">53</xref>].</p></sec><sec id="sec4dot2dot2-viruses-17-00243"><title>4.2.2. HCV Coinfection</title><p>Our analysis showed that concomitant HCV coinfection is associated with higher mortality rates in comparison to HIV mono-infection. The elevation in levels of plasma inflammation and microbial translocation biomarkers, especially soluble CD14 and interleukin-6 in people with HIV/HCV coinfection compared to PWH, have also been previously observed [<xref rid="B54-viruses-17-00243" ref-type="bibr">54</xref>]. HCV-related liver diseases remain a significant cause of morbidity, in-hospital treatment, and mortality of PWH, as HIV/HCV-coinfected individuals experience an accelerated progression of chronic liver disease and higher mortality [<xref rid="B55-viruses-17-00243" ref-type="bibr">55</xref>,<xref rid="B56-viruses-17-00243" ref-type="bibr">56</xref>]. Moreover, HIV/HCV-coinfected individuals have a higher risk of all-cause and non-liver-related deaths and non-liver-related cancers than HCV mono-infected patients [<xref rid="B33-viruses-17-00243" ref-type="bibr">33</xref>]. Morbidity and mortality in this population remain high due to metabolic disorders associated with the occurrence of cardiovascular events [<xref rid="B57-viruses-17-00243" ref-type="bibr">57</xref>]. In our analysis, people with HIV/HCV coinfection who died had significantly higher concentrations of VCAM-1 than those who lived. The elevation of VCAM-1 concentrations in HCV coinfection is common and seems to decrease with HCV eradication [<xref rid="B58-viruses-17-00243" ref-type="bibr">58</xref>]. Limited studies also suggest that VCAM-1 may predict liver-related events and death in patients with HIV/HCV coinfection [<xref rid="B59-viruses-17-00243" ref-type="bibr">59</xref>].</p></sec><sec id="sec4dot2dot3-viruses-17-00243"><title>4.2.3. CVD and Lipid Profile</title><p>Since CVD is one of the main causes of death in PWH, we evaluated the lipid profiles among the study group and observed that in people who died, the concentration of total cholesterol and triglycerides was significantly lower compared to those who lived. However, in multivariable analysis, lipid parameters were not associated with the odds of death. It has been well documented that a significant portion of PWH have impaired lipid profiles that get worse during ART [<xref rid="B60-viruses-17-00243" ref-type="bibr">60</xref>]. Hypothetically, our results might be explained by the fact that 62% of people who died were coinfected with HCV, and chronic HCV infection is associated with low levels of lipid parameters, especially VLDL and LDL. Patients with HCV infection, despite a seemingly beneficial lipid profile, still have accelerated development of atherosclerosis, leading to an increased cardiovascular risk [<xref rid="B61-viruses-17-00243" ref-type="bibr">61</xref>].</p></sec><sec id="sec4dot2dot4-viruses-17-00243"><title>4.2.4. Other Evaluated Risk Factors for Premature Death in PWH</title><p>In our study, age, gender, HBV coinfection, CD4+ cell count, platelet count, and TNF-&#x003b1; were not correlated with the odds of death. According to current research, HIV/HBV coinfection is associated with increased mortality [<xref rid="B62-viruses-17-00243" ref-type="bibr">62</xref>]. Our study group may have included too few patients with HBV coinfection to observe this relationship. Our analysis included only incidental CD4+ cell count measurements, and studies show that the CD4+ lymphocyte nadir is a more important parameter to predict mortality following noncommunicable diseases in PWH [<xref rid="B63-viruses-17-00243" ref-type="bibr">63</xref>]. To our knowledge, even though platelets are involved in inflammatory reactions, there are no direct reports of their impact on mortality [<xref rid="B64-viruses-17-00243" ref-type="bibr">64</xref>]. However, there are suggestions that platelets containing HIV may contribute to a worse immunological response to ART [<xref rid="B65-viruses-17-00243" ref-type="bibr">65</xref>]. Moreover, platelet activation, which is often increased in PWH, may stimulate neutrophil&#x02013;platelet&#x02013;endothelium interactions and, therefore, increase the risk of CVD. This may indirectly be associated with morbidity and mortality of PWH [<xref rid="B66-viruses-17-00243" ref-type="bibr">66</xref>]. Interestingly, in our cohort, the levels of TNF-&#x003b1; were lower in people who died compared to those who lived. Some studies show that the levels of TNF-&#x003b1; in PWH remain high even with long-term ART, but its impact on mortality is currently unknown [<xref rid="B67-viruses-17-00243" ref-type="bibr">67</xref>]. Other research suggests that HIV infection does not have any effect on TNF-&#x003b1; levels, regardless of treatment status [<xref rid="B68-viruses-17-00243" ref-type="bibr">68</xref>].</p><p>In the future, we hope to evaluate additional biomarkers, such as D-dimer, interleukins (including 1&#x003b2;, 6, 11, and 27), and TGF-&#x003b2; as PWH mortality risk factors. D-dimer was the most predictive biomarker of overall mortality in PWH out of a panel of inflammatory and coagulation biomarkers [<xref rid="B69-viruses-17-00243" ref-type="bibr">69</xref>]. Moreover, among HIV/HCV-coinfected patients initiating ART, D-dimer was also associated with an increased risk of death [<xref rid="B70-viruses-17-00243" ref-type="bibr">70</xref>]. Elevated concentrations of interleukins, especially interleukin-6, have been linked with higher mortality rates in men with HIV with undetectable HIV viral loads [<xref rid="B71-viruses-17-00243" ref-type="bibr">71</xref>]. TGF-&#x003b2; expression is an important cancer prognostic factor, and HIV-1 Tat protein triggers TGF-&#x003b2; production; therefore, investigating its association with PWH mortality is a promising approach [<xref rid="B72-viruses-17-00243" ref-type="bibr">72</xref>,<xref rid="B73-viruses-17-00243" ref-type="bibr">73</xref>].</p></sec></sec><sec id="sec4dot3-viruses-17-00243"><title>4.3. Significance and Limitations of the Study</title><p>Our study is significant because of its long follow-up (12 years) and the analysis of multiple biomarkers related to the mortality of PWH. Among analyzed biomarkers, we evaluated PCT in a long-term assessment of PWH, excluding acute patients, which, to our knowledge, has not previously been evaluated as a factor associated with long-term mortality in PWH. However, our study has several limitations. Firstly, the study cohort was relatively small in reliably evaluating the association between the analyzed biomarkers and PWH mortality, which was exacerbated by the fact that we followed up with only 74% of the initial study population. The loss of 26% of patients to follow-up can lead to selection bias, and the variety of analyzed biomarkers in a small study population may pose a risk of type II errors. Secondly, the measurement of analyzed biomarkers was performed only once. Although we included only patients with no signs of acute infection, using single measurements may impact the results. Another limitation is the lack of analysis of ART regimens as a potential risk factor for death, which was impossible to perform because of multiple switches in a limited group of patients. Nevertheless, we believe our observations are an overture to further research using larger populations.</p></sec></sec><sec sec-type="conclusions" id="sec5-viruses-17-00243"><title>5. Conclusions</title><p>Long-term mortality in PWH may be connected to high CRP, PCT, and VCAM-1 concentrations, as well as HCV coinfection. Determining CRP, PCT, and VCAM-1 levels may help identify PWH at increased long-term risk of death for intensified monitoring. PWH should be regularly assessed for HCV coinfection. Care should also be taken for PWH with normal lipid parameters since a beneficial lipid profile is not a sufficient factor to reduce the odds of death.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.L. and T.M.; methodology, A.L.; software, A.L.; validation, A.Z., T.M. and J.K.; formal analysis, A.L.; investigation, A.L.; resources, T.M. and J.K.; data curation, A.L.; writing&#x02014;original draft preparation, A.L.; writing&#x02014;review and editing, A.Z., T.M., and A.W.-D.; visualization, A.L.; supervision, A.W.-D.; project administration, A.L. and T.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Medical University of Warsaw, Poland (AK-BE/128/2021).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data are contained within the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">PWH</td><td align="left" valign="middle" rowspan="1" colspan="1">People with HIV</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ART</td><td align="left" valign="middle" rowspan="1" colspan="1">Antiretroviral therapy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HIV</td><td align="left" valign="middle" rowspan="1" colspan="1">Human immunodeficiency virus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AIDS</td><td align="left" valign="middle" rowspan="1" colspan="1">Acquired immunodeficiency syndrome</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CVD</td><td align="left" valign="middle" rowspan="1" colspan="1">Cardiovascular disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRP</td><td align="left" valign="middle" rowspan="1" colspan="1">C-reactive protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCT</td><td align="left" valign="middle" rowspan="1" colspan="1">Procalcitonin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor necrosis factor alpha</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VCAM-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Vascular cell adhesion molecule 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICAM-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Intercellular adhesion molecule 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HCV</td><td align="left" valign="middle" rowspan="1" colspan="1">Hepatitis C virus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HBV</td><td align="left" valign="middle" rowspan="1" colspan="1">Hepatitis B virus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLT</td><td align="left" valign="middle" rowspan="1" colspan="1">Platelets</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PWID</td><td align="left" valign="middle" rowspan="1" colspan="1">People who inject drugs</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF-&#x003b2;</td><td align="left" valign="middle" rowspan="1" colspan="1">Transforming growth factor beta</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-viruses-17-00243"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barre-Sinoussi</surname><given-names>F.F.</given-names></name>
<name><surname>Chermann</surname><given-names>J.C.</given-names></name>
<name><surname>Rey</surname><given-names>F.</given-names></name>
<name><surname>Nugeyre</surname><given-names>M.T.</given-names></name>
<name><surname>Chamaret</surname><given-names>S.</given-names></name>
<name><surname>Gruest</surname><given-names>J.</given-names></name>
<name><surname>Dauguet</surname><given-names>C.</given-names></name>
<name><surname>Axler-Blin</surname><given-names>C.</given-names></name>
<name><surname>Vezinet-Brun</surname><given-names>F.</given-names></name>
<name><surname>Rouzioux</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)</article-title><source>Science</source><year>1983</year><volume>220</volume><fpage>868</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1126/science.6189183</pub-id><pub-id pub-id-type="pmid">6189183</pub-id>
</element-citation></ref><ref id="B2-viruses-17-00243"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gallo</surname><given-names>R.C.</given-names></name>
<name><surname>Salahuddin</surname><given-names>S.Z.</given-names></name>
<name><surname>Popovic</surname><given-names>M.</given-names></name>
<name><surname>Shearer</surname><given-names>G.M.</given-names></name>
<name><surname>Kaplan</surname><given-names>M.</given-names></name>
<name><surname>Haynes</surname><given-names>B.F.</given-names></name>
<name><surname>Palker</surname><given-names>T.J.</given-names></name>
<name><surname>Redfield</surname><given-names>R.</given-names></name>
<name><surname>Oleske</surname><given-names>J.</given-names></name>
<name><surname>Safai</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS</article-title><source>Science</source><year>1984</year><volume>224</volume><fpage>500</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1126/science.6200936</pub-id><pub-id pub-id-type="pmid">6200936</pub-id>
</element-citation></ref><ref id="B3-viruses-17-00243"><label>3.</label><element-citation publication-type="webpage"><article-title>Fact Sheet&#x02014;Latest Statistics on the Status of the AIDS Epidemic. UNAIDS</article-title><year>2021</year><comment>Available online: <ext-link xlink:href="https://www.unaids.org/en/resources/fact-sheet" ext-link-type="uri">https://www.unaids.org/en/resources/fact-sheet</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-30">(accessed on 30 December 2024)</date-in-citation></element-citation></ref><ref id="B4-viruses-17-00243"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>C.</given-names></name>
<name><surname>Sabin</surname><given-names>C.A.</given-names></name>
<name><surname>Lundgren</surname><given-names>J.D.</given-names></name>
<name><surname>Thiebaut</surname><given-names>R.</given-names></name>
<name><surname>Weber</surname><given-names>R.</given-names></name>
<name><surname>Law</surname><given-names>M.</given-names></name>
<name><surname>Monforte</surname><given-names>A.</given-names></name>
<name><surname>Kirk</surname><given-names>O.</given-names></name>
<name><surname>Friis-Moller</surname><given-names>N.</given-names></name>
<name><surname>Phillips</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study</article-title><source>AIDS</source><year>2010</year><volume>24</volume><fpage>1537</fpage><lpage>1548</lpage><pub-id pub-id-type="pmid">20453631</pub-id>
</element-citation></ref><ref id="B5-viruses-17-00243"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marcus</surname><given-names>J.L.</given-names></name>
<name><surname>Leyden</surname><given-names>W.A.</given-names></name>
<name><surname>Alexeeff</surname><given-names>S.E.</given-names></name>
<name><surname>Anderson</surname><given-names>A.N.</given-names></name>
<name><surname>Hechter</surname><given-names>R.C.</given-names></name>
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Lam</surname><given-names>J.O.</given-names></name>
<name><surname>Towner</surname><given-names>W.J.</given-names></name>
<name><surname>Yuan</surname><given-names>Q.</given-names></name>
<name><surname>Horberg</surname><given-names>M.A.</given-names></name>
<etal/>
</person-group><article-title>Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000&#x02013;2016</article-title><source>JAMA Netw. Open</source><year>2020</year><volume>3</volume><fpage>e207954</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.7954</pub-id><pub-id pub-id-type="pmid">32539152</pub-id>
</element-citation></ref><ref id="B6-viruses-17-00243"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>S.</given-names></name>
<name><surname>Giron</surname><given-names>L.B.</given-names></name>
<name><surname>Shaikh</surname><given-names>M.W.</given-names></name>
<name><surname>Shankaran</surname><given-names>S.</given-names></name>
<name><surname>Engen</surname><given-names>P.A.</given-names></name>
<name><surname>Bogin</surname><given-names>Z.R.</given-names></name>
<name><surname>Bambi</surname><given-names>S.A.</given-names></name>
<name><surname>Goldman</surname><given-names>A.R.</given-names></name>
<name><surname>Azevedo</surname><given-names>J.L.L.C.</given-names></name>
<name><surname>Orgaz</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging</article-title><source>Microbiome</source><year>2024</year><volume>12</volume><elocation-id>31</elocation-id><pub-id pub-id-type="doi">10.1186/s40168-024-01758-4</pub-id><pub-id pub-id-type="pmid">38383483</pub-id>
</element-citation></ref><ref id="B7-viruses-17-00243"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hinton</surname><given-names>A.O.</given-names><suffix>Jr.</suffix></name>
<name><surname>N&#x02019;Jai</surname><given-names>A.U.</given-names></name>
<name><surname>Vue</surname><given-names>Z.</given-names></name>
<name><surname>Wanjalla</surname><given-names>C.</given-names></name>
</person-group><article-title>Connection between HIV and mitochondria in cardiovascular disease and implications for treatments</article-title><source>Circul. Res.</source><year>2024</year><volume>134</volume><fpage>1581</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.124.324296</pub-id></element-citation></ref><ref id="B8-viruses-17-00243"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Francesco</surname><given-names>D.</given-names></name>
<name><surname>Wit</surname><given-names>F.W.</given-names></name>
<name><surname>Burkle</surname><given-names>A.</given-names></name>
<name><surname>Oehlke</surname><given-names>S.</given-names></name>
<name><surname>Kootstra</surname><given-names>N.A.</given-names></name>
<name><surname>Winston</surname><given-names>A.</given-names></name>
<name><surname>Franceschi</surname><given-names>C.</given-names></name>
<name><surname>Garagnani</surname><given-names>P.</given-names></name>
<name><surname>Pirazzini</surname><given-names>C.</given-names></name>
<name><surname>Libert</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Do people living with HIV experience greater age advancement than their HIV-negative counterparts?</article-title><source>AIDS</source><year>2019</year><volume>33</volume><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002063</pub-id><pub-id pub-id-type="pmid">30325781</pub-id>
</element-citation></ref><ref id="B9-viruses-17-00243"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mart&#x000ed;nez-Ayala</surname><given-names>P.</given-names></name>
<name><surname>Alanis-S&#x000e1;nchez</surname><given-names>G.A.</given-names></name>
<name><surname>&#x000c1;lvarez-Zavala</surname><given-names>M.</given-names></name>
<name><surname>S&#x000e1;nchez-Reyes</surname><given-names>K.</given-names></name>
<name><surname>Ruiz-Herrera</surname><given-names>V.V.</given-names></name>
<name><surname>Cabrera-Silva</surname><given-names>R.I.</given-names></name>
<name><surname>Gonz&#x000e1;lez-Hern&#x000e1;ndez</surname><given-names>L.A.</given-names></name>
<name><surname>Ramos-Becerra</surname><given-names>C.</given-names></name>
<name><surname>Cardona Mu&#x000f1;oz</surname><given-names>E.</given-names></name>
<name><surname>Andrade-Villanueva</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Effect of antiretroviral therapy on decreasing arterial stiffness, metabolic profile, vascular and systemic inflammatory cytokines in treatment-na&#x000ef;ve HIV: A one-year prospective study</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0282728</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0282728</pub-id><pub-id pub-id-type="pmid">36930649</pub-id>
</element-citation></ref><ref id="B10-viruses-17-00243"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borges</surname><given-names>&#x000c1;.H.</given-names></name>
<name><surname>O&#x02019;Connor</surname><given-names>J.L.</given-names></name>
<name><surname>Phillips</surname><given-names>A.N.</given-names></name>
<name><surname>R&#x000f6;nsholt</surname><given-names>F.F.</given-names></name>
<name><surname>Pett</surname><given-names>S.</given-names></name>
<name><surname>Vjecha</surname><given-names>M.J.</given-names></name>
<name><surname>French</surname><given-names>M.A.</given-names></name>
<name><surname>Lundgren</surname><given-names>J.D.</given-names></name>
<collab>INSIGHT SMART and ESPRIT Study Groups and the SILCAAT Scientific Committee</collab>
</person-group><article-title>Factors Associated with plasma IL-6 levels during HIV Infection</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>212</volume><fpage>585</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv123</pub-id><pub-id pub-id-type="pmid">25722296</pub-id>
</element-citation></ref><ref id="B11-viruses-17-00243"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Gao</surname><given-names>J.</given-names></name>
<name><surname>Taxman</surname><given-names>D.J.</given-names></name>
<name><surname>Ting</surname><given-names>J.P.</given-names></name>
<name><surname>Su</surname><given-names>L.</given-names></name>
</person-group><article-title>HIV-1 Infection induces interleukin-1&#x003b2; production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>21716</fpage><lpage>21726</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.566620</pub-id><pub-id pub-id-type="pmid">24939850</pub-id>
</element-citation></ref><ref id="B12-viruses-17-00243"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Collora</surname><given-names>J.A.</given-names></name>
<name><surname>Liu</surname><given-names>R.</given-names></name>
<name><surname>Pinto-Santini</surname><given-names>D.</given-names></name>
<name><surname>Ravindra</surname><given-names>N.</given-names></name>
<name><surname>Ganoza</surname><given-names>C.</given-names></name>
<name><surname>Lama</surname><given-names>J.R.</given-names></name>
<name><surname>Alfaro</surname><given-names>R.</given-names></name>
<name><surname>Chiarella</surname><given-names>J.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
<name><surname>Mounzer</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones</article-title><source>Immunity</source><year>2022</year><volume>55</volume><fpage>1013</fpage><lpage>1031.e7</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2022.03.004</pub-id><pub-id pub-id-type="pmid">35320704</pub-id>
</element-citation></ref><ref id="B13-viruses-17-00243"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chinnapaiyan</surname><given-names>S.</given-names></name>
<name><surname>Dutta</surname><given-names>R.K.</given-names></name>
<name><surname>Nair</surname><given-names>M.</given-names></name>
<name><surname>Chand</surname><given-names>H.S.</given-names></name>
<name><surname>Rahman</surname><given-names>I.</given-names></name>
<name><surname>Unwalla</surname><given-names>H.J.</given-names></name>
</person-group><article-title>TGF-&#x003b2;1 increases viral burden and promotes HIV-1 latency in primary differentiated human bronchial epithelial cells</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>12552</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-49056-6</pub-id><pub-id pub-id-type="pmid">31467373</pub-id>
</element-citation></ref><ref id="B14-viruses-17-00243"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pu</surname><given-names>H.</given-names></name>
<name><surname>Tian</surname><given-names>J.</given-names></name>
<name><surname>Flora</surname><given-names>G.</given-names></name>
<name><surname>Lee</surname><given-names>Y.W.</given-names></name>
<name><surname>Nath</surname><given-names>A.</given-names></name>
<name><surname>Hennig</surname><given-names>B.</given-names></name>
<name><surname>Toborek</surname><given-names>M.</given-names></name>
</person-group><article-title>HIV-1 Tat protein upregulates inflamma tory mediators and induces monocyte invasion into the brain</article-title><source>Mol. Cell. Neurosci.</source><year>2003</year><volume>24</volume><fpage>224</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/S1044-7431(03)00171-4</pub-id><pub-id pub-id-type="pmid">14550782</pub-id>
</element-citation></ref><ref id="B15-viruses-17-00243"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>Q.</given-names></name>
<name><surname>Xie</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
</person-group><article-title>The role of CD38 in HIV infection</article-title><source>AIDS Res. Ther.</source><year>2021</year><volume>18</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s12981-021-00330-6</pub-id><pub-id pub-id-type="pmid">33820568</pub-id>
</element-citation></ref><ref id="B16-viruses-17-00243"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Horsburgh</surname><given-names>B.A.</given-names></name>
<name><surname>Lee</surname><given-names>E.</given-names></name>
<name><surname>Hiener</surname><given-names>B.</given-names></name>
<name><surname>Eden</surname><given-names>J.S.</given-names></name>
<name><surname>Schlub</surname><given-names>T.E.</given-names></name>
<name><surname>von Stockenstrom</surname><given-names>S.</given-names></name>
<name><surname>Odevall</surname><given-names>L.</given-names></name>
<name><surname>Milush</surname><given-names>J.M.</given-names></name>
<name><surname>Liegler</surname><given-names>T.</given-names></name>
<name><surname>Sinclair</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>High levels of genetically intact HIV in HLA-DR+ memory T cells indicates their value for reservoir studies</article-title><source>AIDS</source><year>2020</year><volume>4</volume><fpage>659</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002465</pub-id></element-citation></ref><ref id="B17-viruses-17-00243"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Achhra</surname><given-names>A.C.</given-names></name>
<name><surname>Lyass</surname><given-names>A.</given-names></name>
<name><surname>Borowsky</surname><given-names>L.</given-names></name>
<name><surname>Bogorodskaya</surname><given-names>M.</given-names></name>
<name><surname>Plutzky</surname><given-names>J.</given-names></name>
<name><surname>Massaro</surname><given-names>J.M.</given-names></name>
<name><surname>D&#x02019;Agostino</surname><given-names>R.B.</given-names><suffix>Sr.</suffix></name>
<name><surname>Triant</surname><given-names>V.A.</given-names></name>
</person-group><article-title>Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations</article-title><source>Curr. HIV/AIDS Rep.</source><year>2021</year><volume>18</volume><fpage>271</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1007/s11904-021-00567-w</pub-id><pub-id pub-id-type="pmid">34247329</pub-id>
</element-citation></ref><ref id="B18-viruses-17-00243"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Larney</surname><given-names>S.</given-names></name>
<name><surname>Peacock</surname><given-names>A.</given-names></name>
<name><surname>Leung</surname><given-names>J.</given-names></name>
<name><surname>Colledge</surname><given-names>S.</given-names></name>
<name><surname>Hickman</surname><given-names>M.</given-names></name>
<name><surname>Vickerman</surname><given-names>P.</given-names></name>
<name><surname>Grebely</surname><given-names>J.</given-names></name>
<name><surname>Dumchev</surname><given-names>K.V.</given-names></name>
<name><surname>Griffiths</surname><given-names>P.</given-names></name>
<name><surname>Hines</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: A systematic review</article-title><source>Lancet Glob Heal.</source><year>2017</year><volume>5</volume><fpage>e1208</fpage><lpage>e1220</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(17)30373-X</pub-id></element-citation></ref><ref id="B19-viruses-17-00243"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bangsberg</surname><given-names>D.R.</given-names></name>
<name><surname>Hecht</surname><given-names>F.M.</given-names></name>
<name><surname>Clague</surname><given-names>H.</given-names></name>
<name><surname>Charlebois</surname><given-names>E.D.</given-names></name>
<name><surname>Ciccarone</surname><given-names>D.</given-names></name>
<name><surname>Chesney</surname><given-names>M.</given-names></name>
<name><surname>Moss</surname><given-names>A.</given-names></name>
</person-group><article-title>Provider assessment of adherence to HIV antiretroviral therapy</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2001</year><volume>26</volume><fpage>435</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1097/00126334-200104150-00005</pub-id><pub-id pub-id-type="pmid">11391162</pub-id>
</element-citation></ref><ref id="B20-viruses-17-00243"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Freiberg</surname><given-names>M.S.</given-names></name>
<name><surname>Chang</surname><given-names>C.H.</given-names></name>
<name><surname>Skanderson</surname><given-names>M.</given-names></name>
<name><surname>Patterson</surname><given-names>O.V.</given-names></name>
<name><surname>DuVall</surname><given-names>S.L.</given-names></name>
<name><surname>Brandt</surname><given-names>C.A.</given-names></name>
<name><surname>So-Armah</surname><given-names>K.A.</given-names></name>
<name><surname>Vasan</surname><given-names>R.S.</given-names></name>
<name><surname>Oursler</surname><given-names>K.A.</given-names></name>
<name><surname>Gottdiener</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study</article-title><source>JAMA Cardiol.</source><year>2017</year><volume>2</volume><fpage>536</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2017.0264</pub-id><pub-id pub-id-type="pmid">28384660</pub-id>
</element-citation></ref><ref id="B21-viruses-17-00243"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perkins</surname><given-names>M.V.</given-names></name>
<name><surname>Joseph</surname><given-names>S.B.</given-names></name>
<name><surname>Dittmer</surname><given-names>D.P.</given-names></name>
<name><surname>Mackman</surname><given-names>N.</given-names></name>
</person-group><article-title>Cardiovascular Disease and Thrombosis in HIV Infection</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2023</year><volume>43</volume><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.122.318232</pub-id><pub-id pub-id-type="pmid">36453273</pub-id>
</element-citation></ref><ref id="B22-viruses-17-00243"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feinstein</surname><given-names>M.J.</given-names></name>
<name><surname>Bahiru</surname><given-names>E.</given-names></name>
<name><surname>Achenbach</surname><given-names>C.</given-names></name>
<name><surname>Longenecker</surname><given-names>C.T.</given-names></name>
<name><surname>Hsue</surname><given-names>P.</given-names></name>
<name><surname>So-Armah</surname><given-names>K.</given-names></name>
<name><surname>Freiberg</surname><given-names>M.S.</given-names></name>
<name><surname>Lloyd-Jones</surname><given-names>D.</given-names></name>
</person-group><article-title>Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013</article-title><source>Am. J. Cardiol.</source><year>2016</year><volume>117</volume><fpage>214</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2015.10.030</pub-id><pub-id pub-id-type="pmid">26639041</pub-id>
</element-citation></ref><ref id="B23-viruses-17-00243"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alonso</surname><given-names>A.</given-names></name>
<name><surname>Barnes</surname><given-names>A.E.</given-names></name>
<name><surname>Guest</surname><given-names>J.L.</given-names></name>
<name><surname>Shah</surname><given-names>A.</given-names></name>
<name><surname>Shao</surname><given-names>I.Y.</given-names></name>
<name><surname>Marconi</surname><given-names>V.</given-names></name>
</person-group><article-title>HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a Large Healthcare Database</article-title><source>J. Am. Hear. Assoc.</source><year>2019</year><volume>8</volume><fpage>e012241</fpage><pub-id pub-id-type="doi">10.1161/JAHA.119.012241</pub-id><pub-id pub-id-type="pmid">31266386</pub-id>
</element-citation></ref><ref id="B24-viruses-17-00243"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Westra</surname><given-names>J.R.</given-names></name>
<name><surname>Giordano</surname><given-names>T.P.</given-names></name>
<name><surname>Berenson</surname><given-names>A.B.</given-names></name>
<name><surname>Baillargeon</surname><given-names>J.G.</given-names></name>
<name><surname>Kuo</surname><given-names>Y.F.</given-names></name>
</person-group><article-title>Assessing comorbidities and survival in HIV-infected and uninfected matched Medicare enrollees</article-title><source>AIDS</source><year>2021</year><volume>35</volume><fpage>1667</fpage><lpage>1675</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002963</pub-id><pub-id pub-id-type="pmid">34049353</pub-id>
</element-citation></ref><ref id="B25-viruses-17-00243"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trickey</surname><given-names>A.</given-names></name>
<name><surname>McGinnis</surname><given-names>K.</given-names></name>
<name><surname>Gill</surname><given-names>M.J.</given-names></name>
<name><surname>Abgrall</surname><given-names>S.</given-names></name>
<name><surname>Berenguer</surname><given-names>J.</given-names></name>
<name><surname>Wyen</surname><given-names>C.</given-names></name>
<name><surname>Hessamfar</surname><given-names>M.</given-names></name>
<name><surname>Reiss</surname><given-names>P.</given-names></name>
<name><surname>Kusejko</surname><given-names>K.</given-names></name>
<name><surname>Silverberg</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: A collaboration of cohort studies</article-title><source>Lancet HIV</source><year>2024</year><volume>11</volume><fpage>e176</fpage><lpage>e185</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(23)00272-2</pub-id><pub-id pub-id-type="pmid">38280393</pub-id>
</element-citation></ref><ref id="B26-viruses-17-00243"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>Q.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Qian</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Xie</surname><given-names>J.</given-names></name>
<name><surname>Kong</surname><given-names>D.</given-names></name>
</person-group><article-title>Procalcitonin, C-reactive protein, and white blood cell count levels in end-stage cancer patients: A retrospective study on inflammatory markers and their prognostic value</article-title><source>Medicine</source><year>2024</year><volume>103</volume><fpage>e40792</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000040792</pub-id><pub-id pub-id-type="pmid">39654236</pub-id>
</element-citation></ref><ref id="B27-viruses-17-00243"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soeroso</surname><given-names>N.N.</given-names></name>
<name><surname>Tanjung</surname><given-names>M.F.</given-names></name>
<name><surname>Afiani</surname><given-names>D.</given-names></name>
<name><surname>Pradana</surname><given-names>A.</given-names></name>
<name><surname>Tarigan</surname><given-names>S.P.</given-names></name>
<name><surname>Wahyuni</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Procalcitonin Level in Non-Small Cell Lung Cancer Patients among Indonesian Population</article-title><source>Open Access Maced. J. Med. Sci.</source><year>2018</year><volume>6</volume><fpage>2123</fpage><lpage>2127</lpage><pub-id pub-id-type="doi">10.3889/oamjms.2018.421</pub-id><pub-id pub-id-type="pmid">30559873</pub-id>
</element-citation></ref><ref id="B28-viruses-17-00243"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Censi</surname><given-names>S.</given-names></name>
<name><surname>Manso</surname><given-names>J.</given-names></name>
<name><surname>Benvenuti</surname><given-names>T.</given-names></name>
<name><surname>Piva</surname><given-names>I.</given-names></name>
<name><surname>Iacobone</surname><given-names>M.</given-names></name>
<name><surname>Mondin</surname><given-names>A.</given-names></name>
<name><surname>Torresan</surname><given-names>F.</given-names></name>
<name><surname>Basso</surname><given-names>D.</given-names></name>
<name><surname>Crivellari</surname><given-names>G.</given-names></name>
<name><surname>Zovato</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>The role of procalcitonin in the follow-up of medullary thyroid cancer</article-title><source>Eur. Thyroid J.</source><year>2023</year><volume>12</volume><fpage>e220161</fpage><pub-id pub-id-type="doi">10.1530/ETJ-22-0161</pub-id><pub-id pub-id-type="pmid">36476491</pub-id>
</element-citation></ref><ref id="B29-viruses-17-00243"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kong</surname><given-names>D.H.</given-names></name>
<name><surname>Kim</surname><given-names>Y.K.</given-names></name>
<name><surname>Kim</surname><given-names>M.R.</given-names></name>
<name><surname>Jang</surname><given-names>J.H.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
</person-group><article-title>Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>1057</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19041057</pub-id><pub-id pub-id-type="pmid">29614819</pub-id>
</element-citation></ref><ref id="B30-viruses-17-00243"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>VanHeyst</surname><given-names>K.A.</given-names></name>
<name><surname>Choi</surname><given-names>S.H.</given-names></name>
<name><surname>Kingsley</surname><given-names>D.T.</given-names></name>
<name><surname>Huang</surname><given-names>A.Y.</given-names></name>
</person-group><article-title>Ectopic Tumor VCAM-1 Expression in Cancer Metastasis and Therapy Resistance</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>3922</elocation-id><pub-id pub-id-type="doi">10.3390/cells11233922</pub-id><pub-id pub-id-type="pmid">36497180</pub-id>
</element-citation></ref><ref id="B31-viruses-17-00243"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Metcalfe</surname><given-names>R.</given-names></name>
<name><surname>Fraser</surname><given-names>R.</given-names></name>
<name><surname>Trayner</surname><given-names>K.M.A.</given-names></name>
<name><surname>Glancy</surname><given-names>M.</given-names></name>
<name><surname>Yeung</surname><given-names>A.</given-names></name>
<name><surname>Sills</surname><given-names>L.</given-names></name>
<name><surname>Ritchie</surname><given-names>T.</given-names></name>
<name><surname>Priyadarshi</surname><given-names>S.</given-names></name>
<name><surname>Peters</surname><given-names>S.E.</given-names></name>
<name><surname>McAuley</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Rising mortality among people who inject drugs living with HIV in Scotland, UK: A 20-year retrospective cohort study</article-title><source>HIV Med.</source><year>2024</year><volume>18</volume><fpage>265</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1111/hiv.13733</pub-id></element-citation></ref><ref id="B32-viruses-17-00243"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Degenhardt</surname><given-names>L.</given-names></name>
<name><surname>Peacock</surname><given-names>A.</given-names></name>
<name><surname>College</surname><given-names>S.</given-names></name>
<name><surname>Leung</surname><given-names>J.</given-names></name>
<name><surname>Grebely</surname><given-names>J.</given-names></name>
<name><surname>Vickerman</surname><given-names>P.</given-names></name>
<name><surname>Stone</surname><given-names>J.</given-names></name>
<name><surname>Cunningham</surname><given-names>E.B.</given-names></name>
<name><surname>Trickey</surname><given-names>A.</given-names></name>
<name><surname>Dumchev</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review</article-title><source>Lancet Glob. Health</source><year>2017</year><volume>5</volume><fpage>e1192</fpage><lpage>e1207</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(17)30375-3</pub-id><pub-id pub-id-type="pmid">29074409</pub-id>
</element-citation></ref><ref id="B33-viruses-17-00243"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chalouni</surname><given-names>M.</given-names></name>
<name><surname>Pol</surname><given-names>S.</given-names></name>
<name><surname>Sogni</surname><given-names>P.</given-names></name>
<name><surname>Fontaine</surname><given-names>H.</given-names></name>
<name><surname>Lacombe</surname><given-names>K.</given-names></name>
<name><surname>Marc-Lacombe</surname><given-names>J.</given-names></name>
<name><surname>Esterle</surname><given-names>L.</given-names></name>
<name><surname>Dorival</surname><given-names>C.</given-names></name>
<name><surname>Bourli&#x000e8;re</surname><given-names>M.</given-names></name>
<name><surname>Bani-Sadr</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohort study groups. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death</article-title><source>J. Hepatol.</source><year>2021</year><volume>74</volume><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.08.008</pub-id><pub-id pub-id-type="pmid">32798585</pub-id>
</element-citation></ref><ref id="B34-viruses-17-00243"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sazonova</surname><given-names>Y.</given-names></name>
<name><surname>Kulchynska</surname><given-names>R.</given-names></name>
<name><surname>Azarskova</surname><given-names>M.</given-names></name>
<name><surname>Liulchuk</surname><given-names>M.</given-names></name>
<name><surname>Salyuk</surname><given-names>T.</given-names></name>
<name><surname>Doan</surname><given-names>I.</given-names></name>
<name><surname>Barzilay</surname><given-names>E.</given-names></name>
</person-group><article-title>Population-level prevalence of detectable HIV viremia in people who inject drugs (PWID) in Ukraine: Implications for HIV treatment and case finding interventions</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0290661</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0290661</pub-id><pub-id pub-id-type="pmid">37883454</pub-id>
</element-citation></ref><ref id="B35-viruses-17-00243"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Affi</surname><given-names>R.</given-names></name>
<name><surname>Gabillard</surname><given-names>D.</given-names></name>
<name><surname>Kouame</surname><given-names>G.M.</given-names></name>
<name><surname>Ntakpe</surname><given-names>J.B.</given-names></name>
<name><surname>Moh</surname><given-names>R.</given-names></name>
<name><surname>Badje</surname><given-names>A.</given-names></name>
<name><surname>Danel</surname><given-names>C.</given-names></name>
<name><surname>Inwoley</surname><given-names>A.</given-names></name>
<name><surname>Eholi&#x000e9;</surname><given-names>S.P.</given-names></name>
<name><surname>Anglaret</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Plasma sVCAM-1, antiretroviral therapy and mortality in HIV-1-infected west African adults</article-title><source>HIV Med.</source><year>2022</year><volume>23</volume><fpage>717</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1111/hiv.13230</pub-id><pub-id pub-id-type="pmid">35023284</pub-id>
</element-citation></ref><ref id="B36-viruses-17-00243"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Okay</surname><given-names>G.</given-names></name>
<name><surname>Koc</surname><given-names>M.M.</given-names></name>
<name><surname>Guler</surname><given-names>E.M.</given-names></name>
<name><surname>Yabaci</surname><given-names>A.</given-names></name>
<name><surname>Kocyigit</surname><given-names>A.</given-names></name>
<name><surname>Akkoyunlu</surname><given-names>Y.</given-names></name>
</person-group><article-title>The effect of antiretroviral therapy on IL-6, IL-1&#x003b2;, TNF-&#x003b1;, IFN-&#x003b3; levels and their relationship with HIV-RNA and CD4 + T cells in HIV patients</article-title><source>Curr. HIV Res.</source><year>2020</year><volume>18</volume><fpage>354</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.2174/1570162X18666200712174642</pub-id><pub-id pub-id-type="pmid">32652911</pub-id>
</element-citation></ref><ref id="B37-viruses-17-00243"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Teasdale</surname><given-names>C.A.</given-names></name>
<name><surname>Hernandez</surname><given-names>C.</given-names></name>
<name><surname>Zerbe</surname><given-names>A.</given-names></name>
<name><surname>Chege</surname><given-names>D.</given-names></name>
<name><surname>Hawken</surname><given-names>M.</given-names></name>
<name><surname>El-Sadr</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Changes in D-dimer after initiation of antiretroviral therapy in adults living with HIV in Kenya</article-title><source>BMC Inf. Dis.</source><year>2020</year><volume>20</volume><elocation-id>508</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-020-05213-1</pub-id></element-citation></ref><ref id="B38-viruses-17-00243"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharif</surname><given-names>S.</given-names></name>
<name><surname>Van der Graaf</surname><given-names>Y.</given-names></name>
<name><surname>Cramer</surname><given-names>M.J.</given-names></name>
<name><surname>Kapelle</surname><given-names>L.J.</given-names></name>
<name><surname>de Borst</surname><given-names>G.J.</given-names></name>
<name><surname>Visseren</surname><given-names>F.L.J.</given-names></name>
<name><surname>Westerink</surname><given-names>J.</given-names></name>
<collab>SMART study group</collab>
</person-group><article-title>Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 Diabetes</article-title><source>Cardiovasc. Diabetol.</source><year>2021</year><volume>20</volume><fpage>220</fpage><pub-id pub-id-type="doi">10.1186/s12933-021-01409-0</pub-id><pub-id pub-id-type="pmid">34753497</pub-id>
</element-citation></ref><ref id="B39-viruses-17-00243"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reddy</surname><given-names>K.S.S.</given-names></name>
<name><surname>Varadaraj</surname><given-names>P.</given-names></name>
<name><surname>Nallusamy</surname><given-names>G.</given-names></name>
<name><surname>SenthilNathan</surname><given-names>S.</given-names></name>
</person-group><article-title>Correlation Between Hemoglobin A1c (HbA1c) and High-Sensitivity C-Reactive Protein (hs-CRP) in Myocardial Infarction Patients and Their Six-Month Mortality Follow-Up</article-title><source>Cureus</source><year>2024</year><volume>16</volume><fpage>e67070</fpage><pub-id pub-id-type="doi">10.7759/cureus.67070</pub-id><pub-id pub-id-type="pmid">39286672</pub-id>
</element-citation></ref><ref id="B40-viruses-17-00243"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Zhong</surname><given-names>X.</given-names></name>
<name><surname>Cheng</surname><given-names>G.</given-names></name>
<name><surname>Zhao</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Hong</surname><given-names>Y.</given-names></name>
<name><surname>Wan</surname><given-names>Q.</given-names></name>
<name><surname>He</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis</article-title><source>Atherosclerosis</source><year>2017</year><volume>259</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2017.02.003</pub-id><pub-id pub-id-type="pmid">28327451</pub-id>
</element-citation></ref><ref id="B41-viruses-17-00243"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riitho</surname><given-names>V.</given-names></name>
<name><surname>Connon</surname><given-names>R.</given-names></name>
<name><surname>Gwela</surname><given-names>A.</given-names></name>
<name><surname>Namusanje</surname><given-names>J.</given-names></name>
<name><surname>Nhema</surname><given-names>R.</given-names></name>
<name><surname>Siika</surname><given-names>A.</given-names></name>
<name><surname>Bwakura-Dangarembizi</surname><given-names>M.</given-names></name>
<name><surname>Musiime</surname><given-names>V.</given-names></name>
<name><surname>Berkley</surname><given-names>J.A.</given-names></name>
<name><surname>Szubert</surname><given-names>A.J.</given-names></name>
<etal/>
</person-group><article-title>Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>5492</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-49317-7</pub-id><pub-id pub-id-type="pmid">38944653</pub-id>
</element-citation></ref><ref id="B42-viruses-17-00243"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tien</surname><given-names>P.C.</given-names></name>
<name><surname>Choi</surname><given-names>A.I.</given-names></name>
<name><surname>Zolopa</surname><given-names>A.R.</given-names></name>
<name><surname>Benson</surname><given-names>C.</given-names></name>
<name><surname>Tracy</surname><given-names>R.</given-names></name>
<name><surname>Scherzer</surname><given-names>R.</given-names></name>
<name><surname>Bacchetti</surname><given-names>P.</given-names></name>
<name><surname>Shlipak</surname><given-names>M.</given-names></name>
<name><surname>Grunfeld</surname><given-names>C.</given-names></name>
</person-group><article-title>Inflammation and mortality in HIV-infected adults: Analysis of the FRAM study cohort</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2010</year><volume>55</volume><fpage>316</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e3181e66216</pub-id><pub-id pub-id-type="pmid">20581689</pub-id>
</element-citation></ref><ref id="B43-viruses-17-00243"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salter</surname><given-names>M.L.</given-names></name>
<name><surname>Lau</surname><given-names>B.</given-names></name>
<name><surname>Mehta</surname><given-names>S.H.</given-names></name>
<name><surname>Go</surname><given-names>V.F.</given-names></name>
<name><surname>Leng</surname><given-names>S.</given-names></name>
<name><surname>Kirk</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high risk for HCV and HIV infections</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2013</year><volume>64</volume><fpage>488</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e3182a7ee2e</pub-id><pub-id pub-id-type="pmid">23978997</pub-id>
</element-citation></ref><ref id="B44-viruses-17-00243"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parrey</surname><given-names>A.H.</given-names></name>
<name><surname>Koka</surname><given-names>M.</given-names></name>
<name><surname>Kasana</surname><given-names>B.</given-names></name>
<name><surname>Ismail</surname><given-names>M.</given-names></name>
</person-group><article-title>Procalcitonin and qSOFA as a marker of mortality in sepsis</article-title><source>Rev. Recent Clin. Trials</source><year>2024</year><volume>19</volume><fpage>196</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.2174/0115748871288534240322083746</pub-id><pub-id pub-id-type="pmid">38644718</pub-id>
</element-citation></ref><ref id="B45-viruses-17-00243"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sato</surname><given-names>S.</given-names></name>
<name><surname>Sato</surname><given-names>S.</given-names></name>
<name><surname>Tsuzura</surname><given-names>H.</given-names></name>
<name><surname>Ikeda</surname><given-names>Y.</given-names></name>
<name><surname>Hayashida</surname><given-names>S.</given-names></name>
<name><surname>Takahashi</surname><given-names>S.</given-names></name>
<name><surname>Amano</surname><given-names>N.</given-names></name>
<name><surname>Murata</surname><given-names>A.</given-names></name>
<name><surname>Shimada</surname><given-names>Y.</given-names></name>
<name><surname>Iijima</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Elevated serum procalcitonin levels and their association with the prognosis of patients with liver cirrhosis</article-title><source>Eur. J. Gastroenterol. Hepatol.</source><year>2020</year><volume>32</volume><fpage>1222</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000001644</pub-id><pub-id pub-id-type="pmid">31851098</pub-id>
</element-citation></ref><ref id="B46-viruses-17-00243"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000d6;zel</surname><given-names>A.</given-names></name>
<name><surname>Yuce</surname><given-names>S.</given-names></name>
<name><surname>Ilbegi</surname><given-names>E.N.</given-names></name>
</person-group><article-title>Advancing Prognostic Prediction in Pediatric Trauma: The Role of Inflammatory Markers</article-title><source>Klin. Padiatr.</source><year>2024</year><pub-id pub-id-type="doi">10.1055/a-2451-6973</pub-id></element-citation></ref><ref id="B47-viruses-17-00243"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osawa</surname><given-names>T.</given-names></name>
<name><surname>Watanabe</surname><given-names>M.</given-names></name>
<name><surname>Morimoto</surname><given-names>K.</given-names></name>
<name><surname>Okumura</surname><given-names>M.</given-names></name>
<name><surname>Yoshiyama</surname><given-names>T.</given-names></name>
<name><surname>Ogata</surname><given-names>H.</given-names></name>
<name><surname>Goto</surname><given-names>H.</given-names></name>
<name><surname>Kudoh</surname><given-names>S.</given-names></name>
<name><surname>Ohta</surname><given-names>K.</given-names></name>
<name><surname>Sasaki</surname><given-names>Y.</given-names></name>
</person-group><article-title>Serum Procalcitonin Levels Predict Mortality Risk in Patients With Pulmonary Tuberculosis: A Single-Center Prospective Observational Study</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>222</volume><fpage>1651</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiaa275</pub-id><pub-id pub-id-type="pmid">32445568</pub-id>
</element-citation></ref><ref id="B48-viruses-17-00243"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Gu</surname><given-names>K.</given-names></name>
<name><surname>Du</surname><given-names>W.</given-names></name>
<name><surname>Xu</surname><given-names>A.</given-names></name>
</person-group><article-title>Risk factors and prediction model for mortality in HIV/Talaromyces marneffei co-infection: A retrospective cohort study</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e32560</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e32560</pub-id><pub-id pub-id-type="pmid">38961941</pub-id>
</element-citation></ref><ref id="B49-viruses-17-00243"><label>49.</label><element-citation publication-type="gov"><article-title>VCAM1 Vascular Cell Adhesion Molecule 1</article-title><comment>Available online: <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/gene/7412" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/gene/7412</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-20">(accessed on 20 December 2024)</date-in-citation></element-citation></ref><ref id="B50-viruses-17-00243"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andalibi</surname><given-names>M.S.</given-names></name>
<name><surname>Fields</surname><given-names>J.A.</given-names></name>
<name><surname>Iudicello</surname><given-names>J.E.</given-names></name>
<name><surname>Diaz</surname><given-names>M.M.</given-names></name>
<name><surname>Tang</surname><given-names>B.</given-names></name>
<name><surname>Letendre</surname><given-names>S.L.</given-names></name>
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Elevated Biomarkers of Inflammation and Vascular Dysfunction Are Associated with Distal Sensory Polyneuropathy in People with HIV</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>4245</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25084245</pub-id><pub-id pub-id-type="pmid">38673830</pub-id>
</element-citation></ref><ref id="B51-viruses-17-00243"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Graham</surname><given-names>S.M.</given-names></name>
<name><surname>Rajwans</surname><given-names>N.</given-names></name>
<name><surname>Jaoko</surname><given-names>W.</given-names></name>
<name><surname>Estambale</surname><given-names>B.B.</given-names></name>
<name><surname>McClelland</surname><given-names>R.S.</given-names></name>
<name><surname>Overbaugh</surname><given-names>J.</given-names></name>
<name><surname>Liles</surname><given-names>W.C.</given-names></name>
</person-group><article-title>Endothelial activation biomarkers increase after HIV-1 acquisition: Plasma vascular cell adhesion molecule-1 predicts disease progression</article-title><source>AIDS</source><year>2013</year><volume>27</volume><fpage>1803</fpage><lpage>1813</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e328360e9fb</pub-id><pub-id pub-id-type="pmid">23807276</pub-id>
</element-citation></ref><ref id="B52-viruses-17-00243"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Affi</surname><given-names>R.</given-names></name>
<name><surname>Gabillard</surname><given-names>D.</given-names></name>
<name><surname>Dunyach-Remy</surname><given-names>C.</given-names></name>
<name><surname>Ntakpe</surname><given-names>J.B.</given-names></name>
<name><surname>Moh</surname><given-names>R.</given-names></name>
<name><surname>Badje</surname><given-names>A.</given-names></name>
<name><surname>Kouame</surname><given-names>G.M.</given-names></name>
<name><surname>Karcher</surname><given-names>S.</given-names></name>
<name><surname>Le Carrou</surname><given-names>J.</given-names></name>
<name><surname>Danel</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Association of Plasma Soluble Vascular Cell Adhesion Molecule-1 and sCD14 With Mortality in HIV-1-Infected West African Adults With High CD4 Counts</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2021</year><volume>86</volume><fpage>138</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000002533</pub-id><pub-id pub-id-type="pmid">33074857</pub-id>
</element-citation></ref><ref id="B53-viruses-17-00243"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>J.</given-names></name>
<name><surname>Duan</surname><given-names>M.</given-names></name>
<name><surname>Zhuang</surname><given-names>H.</given-names></name>
</person-group><article-title>ICAM1 and VCAM1 are associated with outcome in patients with sepsis: A systematic review and meta-analysis</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e40003</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e40003</pub-id><pub-id pub-id-type="pmid">39559216</pub-id>
</element-citation></ref><ref id="B54-viruses-17-00243"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Juno</surname><given-names>J.A.</given-names></name>
<name><surname>Phetsouphanh</surname><given-names>C.</given-names></name>
<name><surname>Klenerman</surname><given-names>P.</given-names></name>
<name><surname>Kent</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Perturbation of mucosal-associated invariant T cells and iNKT cells in HIV infection</article-title><source>Curr. Opin. HIV AIDS</source><year>2019</year><volume>14</volume><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000526</pub-id><pub-id pub-id-type="pmid">30585802</pub-id>
</element-citation></ref><ref id="B55-viruses-17-00243"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kronfli</surname><given-names>N.</given-names></name>
<name><surname>Bhatnagar</surname><given-names>S.R.</given-names></name>
<name><surname>Hull</surname><given-names>M.W.</given-names></name>
<name><surname>Moodie</surname><given-names>E.E.M.</given-names></name>
<name><surname>Cox</surname><given-names>J.</given-names></name>
<name><surname>Walmsley</surname><given-names>S.</given-names></name>
<name><surname>Gill</surname><given-names>J.</given-names></name>
<name><surname>Cooper</surname><given-names>C.</given-names></name>
<name><surname>Martel-Laferri&#x000e8;re</surname><given-names>V.</given-names></name>
<name><surname>Pick</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Canadian Co-Infection Cohort Investigators. Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up</article-title><source>AIDS</source><year>2019</year><volume>33</volume><fpage>1013</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002156</pub-id><pub-id pub-id-type="pmid">30946155</pub-id>
</element-citation></ref><ref id="B56-viruses-17-00243"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosenthal</surname><given-names>E.</given-names></name>
<name><surname>Roussillon</surname><given-names>C.</given-names></name>
<name><surname>Salmon-C&#x000e9;ron</surname><given-names>D.</given-names></name>
<name><surname>Georget</surname><given-names>A.</given-names></name>
<name><surname>H&#x000e9;nard</surname><given-names>S.</given-names></name>
<name><surname>Huleux</surname><given-names>T.</given-names></name>
<name><surname>Gueit</surname><given-names>I.</given-names></name>
<name><surname>Mortier</surname><given-names>E.</given-names></name>
<name><surname>Costagliola</surname><given-names>D.</given-names></name>
<name><surname>Morlat</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: The Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalit&#x000e9; 2010 survey</article-title><source>HIV Med.</source><year>2015</year><volume>16</volume><fpage>230</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1111/hiv.12204</pub-id><pub-id pub-id-type="pmid">25522874</pub-id>
</element-citation></ref><ref id="B57-viruses-17-00243"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Platt</surname><given-names>L.</given-names></name>
<name><surname>Easterbrook</surname><given-names>P.</given-names></name>
<name><surname>Gower</surname><given-names>E.</given-names></name>
<name><surname>McDonald</surname><given-names>B.</given-names></name>
<name><surname>Sabin</surname><given-names>K.</given-names></name>
<name><surname>McGowan</surname><given-names>C.</given-names></name>
<name><surname>Yanny</surname><given-names>I.</given-names></name>
<name><surname>Razavi</surname><given-names>H.</given-names></name>
<name><surname>Vickerman</surname><given-names>P.</given-names></name>
</person-group><article-title>Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-analysis</article-title><source>Lancet Infect. Dis.</source><year>2016</year><volume>16</volume><fpage>797</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00485-5</pub-id><pub-id pub-id-type="pmid">26922272</pub-id>
</element-citation></ref><ref id="B58-viruses-17-00243"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miku&#x00142;a</surname><given-names>T.</given-names></name>
<name><surname>Suchacz</surname><given-names>M.</given-names></name>
<name><surname>Sapu&#x00142;a</surname><given-names>M.</given-names></name>
<name><surname>Wierci&#x00144;ska-Drapa&#x00142;o</surname><given-names>A.</given-names></name>
</person-group><article-title>Significance of Vascular Cell Adhesion Molecule-1 and Tumor Necrosis Factor-Alpha in HIV-Infected Patients</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>514</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11030514</pub-id><pub-id pub-id-type="pmid">35159966</pub-id>
</element-citation></ref><ref id="B59-viruses-17-00243"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ald&#x000e1;miz-Echevarr&#x000ed;a</surname><given-names>T.</given-names></name>
<name><surname>Berenguer</surname><given-names>J.</given-names></name>
<name><surname>Miralles</surname><given-names>P.</given-names></name>
<name><surname>Jim&#x000e9;nez-Sousa</surname><given-names>M.A.</given-names></name>
<name><surname>Carrero</surname><given-names>A.</given-names></name>
<name><surname>Pineda-Tenor</surname><given-names>D.</given-names></name>
<name><surname>D&#x000ed;ez</surname><given-names>C.</given-names></name>
<name><surname>Tejerina</surname><given-names>F.</given-names></name>
<name><surname>P&#x000e9;rez-Latorre</surname><given-names>L.</given-names></name>
<name><surname>Bell&#x000f3;n</surname><given-names>J.M.</given-names></name>
<etal/>
</person-group><article-title>Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcome</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0148537</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0148537</pub-id><pub-id pub-id-type="pmid">26849641</pub-id>
</element-citation></ref><ref id="B60-viruses-17-00243"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schulte-Hermann</surname><given-names>K.</given-names></name>
<name><surname>Schalk</surname><given-names>H.</given-names></name>
<name><surname>Haider</surname><given-names>B.</given-names></name>
<name><surname>Hutterer</surname><given-names>J.</given-names></name>
<name><surname>Gmeinhart</surname><given-names>B.</given-names></name>
<name><surname>Pichler</surname><given-names>K.</given-names></name>
<name><surname>Brath</surname><given-names>H.</given-names></name>
<name><surname>Dorner</surname><given-names>T.E.</given-names></name>
</person-group><article-title>Impaired lipid profile and insulin resistance in a cohort of Austrian HIV patients</article-title><source>J. Infect. Chemother.</source><year>2016</year><volume>22</volume><fpage>248</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2016.01.007</pub-id><pub-id pub-id-type="pmid">26907935</pub-id>
</element-citation></ref><ref id="B61-viruses-17-00243"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>Kang</surname><given-names>R.</given-names></name>
<name><surname>Zhao</surname><given-names>Z.</given-names></name>
</person-group><article-title>Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e106376</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0106376</pub-id><pub-id pub-id-type="pmid">25184517</pub-id>
</element-citation></ref><ref id="B62-viruses-17-00243"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nikolopoulos</surname><given-names>G.K.</given-names></name>
<name><surname>Paraskevis</surname><given-names>D.</given-names></name>
<name><surname>Psichogiou</surname><given-names>M.</given-names></name>
<name><surname>Hatzakis</surname><given-names>A.</given-names></name>
</person-group><article-title>HBV-DNA levels predict overall mortality in HIV/HBV coinfected individuals</article-title><source>J. Med. Virol.</source><year>2016</year><volume>88</volume><fpage>466</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1002/jmv.24357</pub-id><pub-id pub-id-type="pmid">26288334</pub-id>
</element-citation></ref><ref id="B63-viruses-17-00243"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castilho</surname><given-names>J.L.</given-names></name>
<name><surname>Turner</surname><given-names>M.</given-names></name>
<name><surname>Shepherd</surname><given-names>B.E.</given-names></name>
<name><surname>Koethe</surname><given-names>J.R.</given-names></name>
<name><surname>Furukawa</surname><given-names>S.S.</given-names></name>
<name><surname>Bofill</surname><given-names>C.E.</given-names></name>
<name><surname>Raffanti</surname><given-names>S.</given-names></name>
<name><surname>Sterling</surname><given-names>T.R.</given-names></name>
</person-group><article-title>CD4/CD8 Ratio and CD4 Nadir Predict Mortality Following Noncommunicable Disease Diagnosis in Adults Living with HIV</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2019</year><volume>35</volume><fpage>960</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1089/aid.2019.0064</pub-id><pub-id pub-id-type="pmid">31407605</pub-id>
</element-citation></ref><ref id="B64-viruses-17-00243"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scherlinger</surname><given-names>M.</given-names></name>
<name><surname>Richez</surname><given-names>C.</given-names></name>
<name><surname>Tsokos</surname><given-names>G.C.</given-names></name>
<name><surname>Boilard</surname><given-names>E.</given-names></name>
<name><surname>Blanco</surname><given-names>P.</given-names></name>
</person-group><article-title>The role of platelets in immune-mediated inflammatory diseases</article-title><source>Nat. Rev. Immunol.</source><year>2023</year><volume>23</volume><fpage>495</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1038/s41577-023-00834-4</pub-id><pub-id pub-id-type="pmid">36707719</pub-id>
</element-citation></ref><ref id="B65-viruses-17-00243"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>A.</given-names></name>
<name><surname>Real</surname><given-names>F.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Greffe</surname><given-names>S.</given-names></name>
<name><surname>de Truchis</surname><given-names>P.</given-names></name>
<name><surname>Rouveix</surname><given-names>E.</given-names></name>
<name><surname>Bomsel</surname><given-names>M.</given-names></name>
<name><surname>Capron</surname><given-names>C.</given-names></name>
</person-group><article-title>HIV-Sheltering Platelets From Immunological Non-Responders Induce a Dysfunctional Glycolytic CD4+ T-Cell Profile</article-title><source>Front. Immunol.</source><year>2022</year><volume>12</volume><elocation-id>781923</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.781923</pub-id><pub-id pub-id-type="pmid">35222352</pub-id>
</element-citation></ref><ref id="B66-viruses-17-00243"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Madzime</surname><given-names>M.</given-names></name>
<name><surname>Rossouw</surname><given-names>T.M.</given-names></name>
<name><surname>Theron</surname><given-names>A.J.</given-names></name>
<name><surname>Anderson</surname><given-names>R.</given-names></name>
<name><surname>Steel</surname><given-names>H.C.</given-names></name>
</person-group><article-title>Interactions of HIV and Antiretroviral Therapy With Neutrophils and Platelets</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>634386</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.634386</pub-id><pub-id pub-id-type="pmid">33777022</pub-id>
</element-citation></ref><ref id="B67-viruses-17-00243"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Pablo-Bernal</surname><given-names>R.S.</given-names></name>
<name><surname>Ruiz-Mateos</surname><given-names>E.</given-names></name>
<name><surname>Rosado</surname><given-names>I.</given-names></name>
<name><surname>Dominguez-Molina</surname><given-names>B.</given-names></name>
<name><surname>Alvarez-R&#x000ed;os</surname><given-names>A.I.</given-names></name>
<name><surname>Carrillo-Vico</surname><given-names>A.</given-names></name>
<name><surname>De La Rosa</surname><given-names>R.</given-names></name>
<name><surname>Delgado</surname><given-names>J.</given-names></name>
<name><surname>Mu&#x000f1;oz-Fern&#x000e1;ndez</surname><given-names>M.A.</given-names></name>
<name><surname>Leal</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>TNF-&#x003b1; levels in HIV-infected patients after long-term suppressive cART persist as high as in elderly, HIV-uninfected subjects</article-title><source>J. Antimicrob. Chemother.</source><year>2014</year><volume>69</volume><fpage>3041</fpage><lpage>3046</lpage><pub-id pub-id-type="doi">10.1093/jac/dku263</pub-id><pub-id pub-id-type="pmid">25011654</pub-id>
</element-citation></ref><ref id="B68-viruses-17-00243"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aikpitanyi-Iduitua</surname><given-names>G.A.</given-names></name>
<name><surname>Ibeh</surname><given-names>I.N.</given-names></name>
<name><surname>Idemudia</surname><given-names>N.L.</given-names></name>
<name><surname>Aikpitanyi-Iduitua</surname><given-names>R.O.</given-names></name>
<name><surname>Omoregie</surname><given-names>R.</given-names></name>
</person-group><article-title>Interferon gamma, interleukin 6 and tissue necrosis factor alpha levels among asymptomatic HIV patients in Benin City, Nigeria</article-title><source>Hum. Antibodies</source><year>2022</year><volume>30</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.3233/HAB-220014</pub-id><pub-id pub-id-type="pmid">36641663</pub-id>
</element-citation></ref><ref id="B69-viruses-17-00243"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuller</surname><given-names>L.H.</given-names></name>
<name><surname>Tracy</surname><given-names>R.</given-names></name>
<name><surname>Belloso</surname><given-names>W.</given-names></name>
<name><surname>De Wit</surname><given-names>S.</given-names></name>
<name><surname>Drummond</surname><given-names>F.</given-names></name>
<name><surname>Lane</surname><given-names>H.C.</given-names></name>
<name><surname>Ledergerber</surname><given-names>B.</given-names></name>
<name><surname>Lundgren</surname><given-names>J.</given-names></name>
<name><surname>Neuhaus</surname><given-names>J.</given-names></name>
<name><surname>Nixon</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection</article-title><source>PLoS Med.</source><year>2008</year><volume>5</volume><elocation-id>e203</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0050203</pub-id><pub-id pub-id-type="pmid">18942885</pub-id>
</element-citation></ref><ref id="B70-viruses-17-00243"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andrade</surname><given-names>B.B.</given-names></name>
<name><surname>Hullsiek</surname><given-names>K.H.</given-names></name>
<name><surname>Boulware</surname><given-names>D.R.</given-names></name>
<name><surname>Rupert</surname><given-names>A.</given-names></name>
<name><surname>French</surname><given-names>M.A.</given-names></name>
<name><surname>Ruxrungtham</surname><given-names>K.</given-names></name>
<name><surname>Montes</surname><given-names>M.L.</given-names></name>
<name><surname>Price</surname><given-names>H.</given-names></name>
<name><surname>Barreiro</surname><given-names>P.</given-names></name>
<name><surname>Audsley</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses</article-title><source>J. Infect. Dis.</source><year>2013</year><volume>207</volume><fpage>1379</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit033</pub-id><pub-id pub-id-type="pmid">23335804</pub-id>
</element-citation></ref><ref id="B71-viruses-17-00243"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wada</surname><given-names>N.I.</given-names></name>
<name><surname>Bream</surname><given-names>J.H.</given-names></name>
<name><surname>Mart&#x000ed;nez-Maza</surname><given-names>O.</given-names></name>
<name><surname>Macatangay</surname><given-names>B.</given-names></name>
<name><surname>Galvin</surname><given-names>S.R.</given-names></name>
<name><surname>Margolick</surname><given-names>J.B.</given-names></name>
<name><surname>Jacobson</surname><given-names>L.P.</given-names></name>
</person-group><article-title>Inflammatory Biomarkers and Mortality Risk Among HIV-Suppressed Men: A Multisite Prospective Cohort Study</article-title><source>Clin. Infect. Dis.</source><year>2016</year><volume>63</volume><fpage>984</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw409</pub-id><pub-id pub-id-type="pmid">27343547</pub-id>
</element-citation></ref><ref id="B72-viruses-17-00243"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Shen</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Lai</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Che</surname><given-names>G.</given-names></name>
</person-group><article-title>Prognostic value of TGF-&#x003b2; in lung cancer: Systematic review and meta-analysis</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><elocation-id>691</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-019-5917-5</pub-id><pub-id pub-id-type="pmid">31307405</pub-id>
</element-citation></ref><ref id="B73-viruses-17-00243"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poggi</surname><given-names>A.</given-names></name>
<name><surname>Zocchi</surname><given-names>M.R.</given-names></name>
</person-group><article-title>HIV-1 Tat triggers TGF-beta production and NK cell apoptosis that is prevented by pertussis toxin B</article-title><source>Clin. Dev. Immunol.</source><year>2006</year><volume>13</volume><fpage>369</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">17162379</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-00243-f001"><label>Figure 1</label><caption><p>The Kaplan&#x02013;Meier curve for study population survival.</p></caption><graphic xlink:href="viruses-17-00243-g001" position="float"/></fig><fig position="float" id="viruses-17-00243-f002"><label>Figure 2</label><caption><p>The ROC curves for VCAM-1 and TNF-&#x003b1;. (<bold>a</bold>) ROC curve for VCAM-1. (<bold>b</bold>) ROC curve for TNF-&#x003b1;.</p></caption><graphic xlink:href="viruses-17-00243-g002" position="float"/></fig><table-wrap position="float" id="viruses-17-00243-t001"><object-id pub-id-type="pii">viruses-17-00243-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline data of all analyzed patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">All Patients (<italic toggle="yes">n</italic> = 72)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients Who Lived (<italic toggle="yes">n</italic> = 40)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients Who Died (<italic toggle="yes">n</italic> = 13)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age (years) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">38.68 (11.04)</td><td align="center" valign="middle" rowspan="1" colspan="1">37.73 (11.42)</td><td align="center" valign="middle" rowspan="1" colspan="1">40.85 (11.52)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.153</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male gender (n (%))</td><td align="center" valign="middle" rowspan="1" colspan="1">56 (77.78)</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (77.50)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (84.62)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.711</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female gender (n (%))</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (22.22)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (22.50)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (15.38)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.711</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Intravenous drug use (n (%))</td><td align="center" valign="middle" rowspan="1" colspan="1">39 (54.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (45.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (84.62)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.013</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HCV coinfection (n (%))</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (36.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (25.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (61.54)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HBV coinfection (n (%))</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (18.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (15.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (30.77)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.237</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duration of HIV infection (years) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">4.48 (5.21)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.80 (3.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.54 (6.80)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duration of HIV treatment (weeks) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">93.50 (142.28)</td><td align="center" valign="middle" rowspan="1" colspan="1">76.28 (126.44)</td><td align="center" valign="middle" rowspan="1" colspan="1">116.61 (181.23)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.355</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PLT (G/L) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">217.82 (99.59)</td><td align="center" valign="middle" rowspan="1" colspan="1">225.88 (111.34)</td><td align="center" valign="middle" rowspan="1" colspan="1">182.46 (90.98)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.209</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CRP (mg/L) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">22.10 (44.61)</td><td align="center" valign="middle" rowspan="1" colspan="1">10.75 (15.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">39.17 (50.42)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PCT (ng/mL) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72 (3.98)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05 (0.01)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36 (0.60)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VCAM-1 (ng/mL) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">912.00 (68.52)</td><td align="center" valign="middle" rowspan="1" colspan="1">729.10 (556.28)</td><td align="center" valign="middle" rowspan="1" colspan="1">1574.54 (770.91)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TNF-&#x003b1; (pg/mL) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">64.55 (64.99)</td><td align="center" valign="middle" rowspan="1" colspan="1">67.96 (79.82)</td><td align="center" valign="middle" rowspan="1" colspan="1">48.71 (24.96)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.113</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4+ cell count (cells/&#x003bc;L) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">294.47 (210.60)</td><td align="center" valign="middle" rowspan="1" colspan="1">280.95 (204.23)</td><td align="center" valign="middle" rowspan="1" colspan="1">191.31 (111.84)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.085</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total cholesterol (mmol/L) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">4.18 (1.20)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.27 (0.95)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.41 (1.28)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LDL cholesterol (mmol/L) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">2.43 (1.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.58 (0.83)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.69 (0.76)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.316</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HDL cholesterol (mmol/L) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">1.15 (0.41)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.30 (0.82)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.95 (0.93)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.120</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Triglycerides (mmol/L) (mean (SD))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.70 (0.86)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.18 (0.35)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82 (0.28)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00243-t002"><object-id pub-id-type="pii">viruses-17-00243-t002_Table 2</object-id><label>Table 2</label><caption><p>Factors associated with the risk of death in people with HIV by univariate and multivariable logistic regression analysis. The analysis compared patients who died with those who lived who stayed in care for the whole observation period.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">OR (95% CI)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">aOR * (95% CI)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td colspan="5" align="left" valign="middle" rowspan="1">Age</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;35 years (<italic toggle="yes">n</italic> = 23)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;35 years (<italic toggle="yes">n</italic> = 30)</td><td align="left" valign="middle" rowspan="1" colspan="1">6.08 (1.19&#x02013;31.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.030</td><td align="left" valign="middle" rowspan="1" colspan="1">4.01 (0.75&#x02013;21.49)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.104</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">Gender</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male (<italic toggle="yes">n</italic> = 42)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female (<italic toggle="yes">n</italic> = 11)</td><td align="left" valign="middle" rowspan="1" colspan="1">2.86 (0.32&#x02013;25.80)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.350</td><td align="left" valign="middle" rowspan="1" colspan="1">2.84 (0.31&#x02013;26.76)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.362</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Intravenous drug use</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No (<italic toggle="yes">n</italic> = 24)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes (<italic toggle="yes">n</italic> = 29)</td><td align="left" valign="middle" rowspan="1" colspan="1">6.72 (1.32&#x02013;34.32)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.009</td><td align="left" valign="middle" rowspan="1" colspan="1">6.59 (1.22&#x02013;35.66)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.029</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">HCV infection</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No (<italic toggle="yes">n</italic> = 35)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes (<italic toggle="yes">n</italic> = 18)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.80 (1.27&#x02013;18.09)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.021</td><td align="left" valign="middle" rowspan="1" colspan="1">5.64 (1.17&#x02013;27.22)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.031</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">HBV infection</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No (<italic toggle="yes">n</italic> = 43)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes (<italic toggle="yes">n</italic> = 10)</td><td align="left" valign="middle" rowspan="1" colspan="1">2.52 (0.58&#x02013;10.88)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.216</td><td align="left" valign="middle" rowspan="1" colspan="1">2.46 (0.51&#x02013;11.85)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.262</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">CD4+ cell count</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;200 cells/&#x003bc;L (<italic toggle="yes">n</italic> = 35)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;200 cells/&#x003bc;L (<italic toggle="yes">n</italic> = 17)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.46 (0.40&#x02013;5.38)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.571</td><td align="left" valign="middle" rowspan="1" colspan="1">1.70 (0.37&#x02013;7.91)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.498</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">PLT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;140 G/L (<italic toggle="yes">n</italic> = 40)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;140 G/L (<italic toggle="yes">n</italic> = 13)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.53 (0.38&#x02013;6.16)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.549</td><td align="left" valign="middle" rowspan="1" colspan="1">2.63 (0.52&#x02013;13.29)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.242</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">CRP</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5 mg/L (<italic toggle="yes">n</italic> = 28)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;5 mg/L (<italic toggle="yes">n</italic> = 25)</td><td align="left" valign="middle" rowspan="1" colspan="1">5.56 (1.32&#x02013;23.46)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.020</td><td align="left" valign="middle" rowspan="1" colspan="1">20.65 (1.88&#x02013;227.24)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCT</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;0.05 ng/mL (<italic toggle="yes">n</italic> = 44)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;0.05 ng/mL (<italic toggle="yes">n</italic> = 9)</td><td align="left" valign="middle" rowspan="1" colspan="1">22.17 (3.69&#x02013;133.02)</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="middle" rowspan="1" colspan="1">16.60 (2.43&#x02013;113.20)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VCAM-1</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;922 ng/mL (<italic toggle="yes">n</italic> = 33)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;922 ng/mL (<italic toggle="yes">n</italic> = 20)</td><td align="left" valign="middle" rowspan="1" colspan="1">48.00 (5.41&#x02013;425.56)</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="middle" rowspan="1" colspan="1">33.49 (3.54&#x02013;316.98)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;43.45 pg/mL (<italic toggle="yes">n</italic> = 22)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;43.45 pg/mL (<italic toggle="yes">n</italic> = 31)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.34 (0.09&#x02013;1.23)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.099</td><td align="left" valign="middle" rowspan="1" colspan="1">0.30 (0.07&#x02013;1.35)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.116</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total cholesterol</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;4.91 mmol/L (<italic toggle="yes">n</italic> = 44)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;4.91 mmol/L (<italic toggle="yes">n</italic> = 9)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.33 (0.04&#x02013;2.96)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.324</td><td align="left" valign="middle" rowspan="1" colspan="1">0.24 (0.00&#x02013;5.64)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.997</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HDL cholesterol</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003e;1 mmol/L (<italic toggle="yes">n</italic> = 34)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02264;1 mmol/L (<italic toggle="yes">n</italic> = 19)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.22 (1.13&#x02013;15.72)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.032</td><td align="left" valign="middle" rowspan="1" colspan="1">2.67 (0.62&#x02013;11.56)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.188</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LDL cholesterol</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2.6 mmol/L (<italic toggle="yes">n</italic> = 40)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;2.6 mmol/L (<italic toggle="yes">n</italic> = 13)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.19 (0.02&#x02013;1.67)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.135</td><td align="left" valign="middle" rowspan="1" colspan="1">0.17 (0.00&#x02013;3.78)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.998</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Triglyceride</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1.7 mmol/L (<italic toggle="yes">n</italic> = 38)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;1.7 mmol/L (<italic toggle="yes">n</italic> = 15)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.88 (0.50&#x02013;7.07)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.353</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.60 (0.35&#x02013;7.28)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.543</td></tr></tbody></table><table-wrap-foot><fn><p>* aOR&#x02014;adjusted odds ratio. The odds ratio was adjusted in the multivariate logistic model by age (&#x0003c;35 years old vs. &#x02265;35 years old) and gender (male vs. female).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-17-00243-t003"><object-id pub-id-type="pii">viruses-17-00243-t003_Table 3</object-id><label>Table 3</label><caption><p>Factors associated with the risk of death in PWH who inject drugs by univariate and multivariable logistic regression analysis. The analysis compared patients who died and those who lived who stayed in care for the whole observation period.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">OR (95% CI)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">aOR * (95% CI)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td colspan="5" align="left" valign="middle" rowspan="1">Age</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;35 years (<italic toggle="yes">n</italic> = 11)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;35 years (<italic toggle="yes">n</italic> = 18)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.50 (0.75&#x02013;26.93)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.100</td><td align="left" valign="middle" rowspan="1" colspan="1">4.93 (0.73&#x02013;33.21)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.764</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">Gender</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male (<italic toggle="yes">n</italic> = 23)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female (<italic toggle="yes">n</italic> = 7)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.50 (0.43&#x02013;5.21)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.523</td><td align="left" valign="middle" rowspan="1" colspan="1">1.72 (0.08&#x02013;6.18)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.362</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">HCV infection</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No (<italic toggle="yes">n</italic> = 15)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes (<italic toggle="yes">n</italic> = 14)</td><td align="left" valign="middle" rowspan="1" colspan="1">5.33 (1.03&#x02013;27.76)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.047</td><td align="left" valign="middle" rowspan="1" colspan="1">6.18 (1.03&#x02013;36.89)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.046</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">HBV infection</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No (<italic toggle="yes">n</italic> = 22)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes (<italic toggle="yes">n</italic> = 7)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.31 (0.23&#x02013;7.41)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.758</td><td align="left" valign="middle" rowspan="1" colspan="1">1.01 (0.14&#x02013;7.46)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.996</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">CD4+ cell count</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;200 cells/&#x003bc;L (<italic toggle="yes">n</italic> = 22)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;200 cells/&#x003bc;L (<italic toggle="yes">n</italic> = 7)</td><td align="left" valign="middle" rowspan="1" colspan="1">2.86 (0.50&#x02013;16.36)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.238</td><td align="left" valign="middle" rowspan="1" colspan="1">2.84 (0.37&#x02013;21.57)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.314</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">PLT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;140 G/L (<italic toggle="yes">n</italic> = 24)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;140 G/L (<italic toggle="yes">n</italic> = 5)</td><td align="left" valign="middle" rowspan="1" colspan="1">3.00 (0.41&#x02013;21.74)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.277</td><td align="left" valign="middle" rowspan="1" colspan="1">2.44 (0.27&#x02013;21.97)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.426</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">CRP</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5 mg/L (<italic toggle="yes">n</italic> = 13)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;5 mg/L (<italic toggle="yes">n</italic> = 16)</td><td align="left" valign="middle" rowspan="1" colspan="1">7.07 (1.17&#x02013;42.85)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.033</td><td align="left" valign="middle" rowspan="1" colspan="1">9.42 (1.30&#x02013;68.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.026</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCT</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;0.05 ng/mL (<italic toggle="yes">n</italic> = 6)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;0.05 ng/mL (<italic toggle="yes">n</italic> = 23)</td><td align="left" valign="middle" rowspan="1" colspan="1">7.06 (0.00&#x02013;250.09)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.997</td><td align="left" valign="middle" rowspan="1" colspan="1">25.09 (0.00&#x02013;286.89)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.997</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VCAM-1</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;922 ng/mL (<italic toggle="yes">n</italic> = 14)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;922 ng/mL (<italic toggle="yes">n</italic> = 15)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.50 (0.75&#x02013;26.93)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.099</td><td align="left" valign="middle" rowspan="1" colspan="1">3.28 (0.36&#x02013;35.78)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.994</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;43.45 pg/mL (<italic toggle="yes">n</italic> = 19)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;43.45 pg/mL (<italic toggle="yes">n</italic> = 10)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.47 (0.14&#x02013;1.56)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.218</td><td align="left" valign="middle" rowspan="1" colspan="1">0.29 (0.05&#x02013;1.74)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.117</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total cholesterol</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;4.91 mmol/L (<italic toggle="yes">n</italic> = 25)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;4.91 mmol/L (<italic toggle="yes">n</italic> = 4)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.50 (0.05&#x02013;5.51)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.571</td><td align="left" valign="middle" rowspan="1" colspan="1">0.26 (0.02&#x02013;3.17)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.288</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HDL cholesterol</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003e;1 mmol/L (<italic toggle="yes">n</italic> = 17)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02264;1 mmol/L (<italic toggle="yes">n</italic> = 12)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.55 (0.92&#x02013;22.63)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.064</td><td align="left" valign="middle" rowspan="1" colspan="1">3.28 (0.60&#x02013;17.98)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.172</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LDL cholesterol</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2.6 mmol/L (<italic toggle="yes">n</italic> = 21)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;2.6 mmol/L (<italic toggle="yes">n</italic> = 8)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.16 (0.02&#x02013;1.51)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.109</td><td align="left" valign="middle" rowspan="1" colspan="1">0.06 (0.01&#x02013;0.69)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.052</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Triglyceride</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1.7 mmol/L (<italic toggle="yes">n</italic> = 21)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;1.7 mmol/L (<italic toggle="yes">n</italic> = 8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.00 (0.38&#x02013;10.48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.412</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.89 (0.30&#x02013;11.94)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.497</td></tr></tbody></table><table-wrap-foot><fn><p>* aOR&#x02014;adjusted odds ratio. The odds ratio was adjusted in the multivariate logistic model by age (&#x0003c;35 years old vs. &#x02265;35 years old) and gender (male vs. female).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-17-00243-t004"><object-id pub-id-type="pii">viruses-17-00243-t004_Table 4</object-id><label>Table 4</label><caption><p>Factors associated with the risk of cancer incidence in PWH&#x02014;univariate and multivariable logistic regression analysis. The analysis compared patients who died and those who lived who stayed in care for the whole observation period.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">OR (95% CI)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">aOR * (95% CI)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td colspan="5" align="left" valign="middle" rowspan="1">Age</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;35 years (<italic toggle="yes">n</italic> = 22)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;35 years (<italic toggle="yes">n</italic> = 25)</td><td align="left" valign="middle" rowspan="1" colspan="1">6.63 (0.73&#x02013;60.22)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.093</td><td align="left" valign="middle" rowspan="1" colspan="1">7.86 (0.80&#x02013;77.16)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.077</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">Gender</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male (<italic toggle="yes">n</italic> = 36)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female (<italic toggle="yes">n</italic> = 11)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.73 (0.12&#x02013;4.39)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.726</td><td align="left" valign="middle" rowspan="1" colspan="1">0.45 (0.06&#x02013;3.29)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.434</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Intravenous drug use</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No (<italic toggle="yes">n</italic> = 24)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes (<italic toggle="yes">n</italic> = 23)</td><td align="left" valign="middle" rowspan="1" colspan="1">3.06 (0.53&#x02013;17.66)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.212</td><td align="left" valign="middle" rowspan="1" colspan="1">3.00 (0.48&#x02013;18.73)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.239</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">HCV infection</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No (<italic toggle="yes">n</italic> = 33)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes (<italic toggle="yes">n</italic> = 14)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.00 (0.76&#x02013;21.02)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.102</td><td align="left" valign="middle" rowspan="1" colspan="1">6.89 (1.00&#x02013;46.69)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.051</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">HBV infection</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No (<italic toggle="yes">n</italic> = 39)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes (<italic toggle="yes">n</italic> = 8)</td><td align="left" valign="middle" rowspan="1" colspan="1">2.27 (0.35&#x02013;14.49)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.387</td><td align="left" valign="middle" rowspan="1" colspan="1">1.37 (0.18&#x02013;10.27)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.759</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">CD4+ cell count</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;200 cells/&#x003bc;L (<italic toggle="yes">n</italic> = 31)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;200 cells/&#x003bc;L (<italic toggle="yes">n</italic> = 16)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.67 (0.75&#x02013;29.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.098</td><td align="left" valign="middle" rowspan="1" colspan="1">4.39 (0.65&#x02013;29.53)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.128</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">PLT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;140 G/L (<italic toggle="yes">n</italic> = 34)</td><td colspan="4" align="left" valign="middle" rowspan="1">Ref.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;140 G/L (<italic toggle="yes">n</italic> = 13)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.59 (0.86&#x02013;24.42)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.074</td><td align="left" valign="middle" rowspan="1" colspan="1">5.15 (0.76&#x02013;34.84)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.093</td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1">CRP</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5 mg/L (<italic toggle="yes">n</italic> = 27)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;5 mg/L (<italic toggle="yes">n</italic> = 20)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.17 (0.72&#x02013;24.23)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.112</td><td align="left" valign="middle" rowspan="1" colspan="1">4.41 (0.70&#x02013;27.84)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.115</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCT</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;0.05 ng/mL (<italic toggle="yes">n</italic> = 41)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;0.05 ng/mL (<italic toggle="yes">n</italic> = 6)</td><td align="left" valign="middle" rowspan="1" colspan="1">25.33 (3.21&#x02013;199.69)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.002</td><td align="left" valign="middle" rowspan="1" colspan="1">18.41 (1.84&#x02013;183.98)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VCAM-1</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;922 ng/mL (<italic toggle="yes">n</italic> = 33)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;922 ng/mL (<italic toggle="yes">n</italic> = 14)</td><td align="left" valign="middle" rowspan="1" colspan="1">24.00 (2.52&#x02013;228.70)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.006</td><td align="left" valign="middle" rowspan="1" colspan="1">19.09 (1.92&#x02013;189.82)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;43.45 pg/mL (<italic toggle="yes">n</italic> = 20)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;43.45 pg/mL (<italic toggle="yes">n</italic> = 27)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.09 (0.01&#x02013;0.82)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.033</td><td align="left" valign="middle" rowspan="1" colspan="1">0.11 (0.01&#x02013;1.08)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.058</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total cholesterol</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;4.91 mmol/L (<italic toggle="yes">n</italic> = 38)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;4.91 mmol/L (<italic toggle="yes">n</italic> = 9)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.67 (0.07&#x02013;6.35)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.724</td><td align="left" valign="middle" rowspan="1" colspan="1">9.18 (0.90&#x02013;93.99)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.465</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HDL cholesterol</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003e;1 mmol/L (<italic toggle="yes">n</italic> = 32)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02264;1 mmol/L (<italic toggle="yes">n</italic> = 15)</td><td align="left" valign="middle" rowspan="1" colspan="1">3.52 (0.68&#x02013;18.30)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.135</td><td align="left" valign="middle" rowspan="1" colspan="1">2.97 (0.51&#x02013;17.17)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.225</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LDL cholesterol</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2.6 mmol/L (<italic toggle="yes">n</italic> = 34)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;2.6 mmol/L (<italic toggle="yes">n</italic> = 13)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.39 (0.04&#x02013;3.59)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.405</td><td align="left" valign="middle" rowspan="1" colspan="1">0.22 (0.02&#x02013;2.26)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.205</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Triglyceride</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1.7 mmol/L (<italic toggle="yes">n</italic> = 34)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;1.7 mmol/L (<italic toggle="yes">n</italic> = 13)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.25 (0.43&#x02013;11.83)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.338</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.32 (0.35&#x02013;15.30)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.380</td></tr></tbody></table><table-wrap-foot><fn><p>* aOR&#x02014;adjusted odds ratio. The odds ratio was adjusted in the multivariate logistic model by age (&#x0003c;35 years old vs. &#x02265;35 years old) and gender (male vs. female).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-17-00243-t005"><object-id pub-id-type="pii">viruses-17-00243-t005_Table 5</object-id><label>Table 5</label><caption><p>Differences in analyzed parameters in HIV/HCV-coinfected individuals depending on mortality. The analysis compared patients who died and those who lived who stayed in care for the whole observation period.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">All HIV/HCV-Coinfected Patients (<italic toggle="yes">n</italic> = 18)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients Who Lived (<italic toggle="yes">n</italic> = 10)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients Who Died (<italic toggle="yes">n</italic> = 8)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age (years) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">35.94 (6.66)</td><td align="center" valign="middle" rowspan="1" colspan="1">33.80 (6.81)</td><td align="center" valign="middle" rowspan="1" colspan="1">38.63 (5.78)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.130</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male gender (n (%))</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (77.78)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (80.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (75.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.800</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female gender (n (%))</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (22.22)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (20.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (25.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.800</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Intravenous drug use (n (%))</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (77.78)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (60.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (100.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.196</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HBV coinfection (n (%))</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (16.67)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (10.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (25.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.466</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duration of HIV infection (years) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">5.42 (6.53)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.65 (3.73)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.88 (7.81)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.322</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duration of HIV treatment (weeks) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">86.39 (168.59)</td><td align="center" valign="middle" rowspan="1" colspan="1">82.50 (176.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">91.25 (170.67)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.427</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PLT (G/L) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">215.17 (128.37)</td><td align="center" valign="middle" rowspan="1" colspan="1">236.20 (156.64)</td><td align="center" valign="middle" rowspan="1" colspan="1">188.88 (83.96)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.454</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CRP (mg/L) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">18.83 (23.32)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.30 (23.36)</td><td align="center" valign="middle" rowspan="1" colspan="1">24.50 (24.66)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.252</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PCT (ng/mL) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11 (0.20)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05 (0.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17 (0.30)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.056</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VCAM-1 (ng/mL) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">1234.67 (925.33)</td><td align="center" valign="middle" rowspan="1" colspan="1">797.60 (786.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">1781.00 (819.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TNF-&#x003b1; (pg/mL) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">54.87 (23.46)</td><td align="center" valign="middle" rowspan="1" colspan="1">56.49 (21.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">52.84 (27.49)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.374</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4+ cell count (cells/&#x003bc;L) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">253.89 (203.67)</td><td align="center" valign="middle" rowspan="1" colspan="1">313.00 (258.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">180.00 (62.66)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.504</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total cholesterol (mmol/L) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">3.88 (1.02)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.07 (0.82)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.65 (1.24)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.395</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LDL cholesterol (mmol/L) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">2.14 (0.74)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.06 (0.59)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.23 (0.93)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.924</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HDL cholesterol (mmol/L) (mean (SD))</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04 (0.36)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25 (0.28)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.78 (0.27)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Triglycerides (mmol/L) (mean (SD))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.72 (0.89)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.65 (0.91)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.80 (0.91)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.964</td></tr></tbody></table></table-wrap></floats-group></article>